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ABSTRACT 
 
 EPH (Erythropoietin-Producing Hepatocellular carcinoma cell line) 
receptor tyrosine kinases (RTK) belong to the largest subfamily of RTKs 
counting 14 genes in humans. Among them, EPHA2 is often overexpressed in 
a variety of human cancers, including thyroid carcinoma. Thyroid carcinomas 
are commonly driven by genetic lesions targeting the MAPK signaling cascade 
including rearrangements of several RTKs, such as RET and NTRK, or point 
mutations in RAS or BRAF. We have previously demonstrated, through a 
siRNA-based genetic screen of the human kinome, that EPHA2 expression is 
essential for viability of thyroid cancer cells in culture. To gain insight into the 
EPHA2 function in thyroid tumorigenesis, we studied the role of the 
intracellular domain of EPHA2 and, in particular, of its phosphorylation on 
Serine 897 (pSer897). Ser897 phosphorylation has been previously reported to 
mediate EPHA2 oncogenic activity. Ser897 is embedded in the consensus 
phosphorylation sequence for AGC (PKA, PKG, PKC) family kinases, 
including p90RSK, a direct MAPK target. Here we show that in thyroid cancer 
cells bearing oncogenic lesions in the MAPK signaling cascade, EPHA2 is 
robustly phosphorylated on Ser897. Treatment with chemical inhibitors 
targeting p90RSK or other MAPK pathway components blunts Ser897 
phosphorylation of EPHA2. Recombinant p90RSK phosphorylates in vitro 
EPHA2 Ser897. Finally, RNA interference-mediated knock-down combined 
with rescue experiments demonstrate that Ser897 phosphorylation of EPHA2 
mediates thyroid cancer cell proliferation and motility. Collectively, these 
findings point to EPHA2 pSer897 as a novel crucial mediator of the oncogenic 
MAPK signaling cascade, and in particular of p90RSK, in thyroid cancer. 
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1. INTRODUCTION 
 
1.1 Thyroid cancer 
 
Thyroid carcinoma is a relatively rare neoplasm, representing about 1% of all 
cancers (Tuttle et al. 2014). Nonetheless, thyroid cancer is the most common 
malignant endocrine tumor and its incidence has been stably increasing over 
the past few decades (Fallahi et al. 2014; Frampton 2016). According to the 
Surveillance Epidemiology and End Results (SEER) database, the rate of new 
thyroid cancer cases have risen on average 5% per year. The increased thyroid 
cancer incidence is probably due to the development of high-resolution 
imaging techniques and early diagnosis upon fine needle-aspiration biopsy 
(FNAB) (Zevallos et al. 2015). However, other potential causes, such as 
exposure to ionizing radiation, iodine deficiency, autoimmune thyroiditis and 
chronic infections (Antonelli et al. 2007; Ferrari et al. 2015; Su et al. 2016), as 
well as increased life expectancy (Kwong et al. 2015; Su et al. 2016) cannot be 
excluded.  
 The vast majority of thyroid cancers derives from follicular cells 
(thyrocytes) that normally secrete thyroglobulin (TG) and thyroid hormones 
(thyroxine-T4 and triiodothyronine-T3). Instead, approximately 5% of thyroid 
carcinomas originate from para-follicular thyroid cells (C-cells, secreting 
calcitonin); calcitonin-secreting thyroid carcinomas are called medullary 
thyroid carcinoma (MTC). MTC occurs either sporadically (75%) or as a 
dominantly inherited disease in the context of multiple endocrine neoplasia 
(MEN) type 2 (MEN2A or MEN2B) [Ferrari et al. 2015].  
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 Histological examination of the thyroid gland of patients affected by the 
hereditary form of the disease shows a widespread C-cell hyperplasia (CCH) 
suggesting that hyperplasia is an early event in C cell transformation (Hinze et 
al. 1998; Wells et al. 2015). 
 The follicular cell-derived thyroid carcinomas include several 
histological histotypes; according to their malignancy and differentiation grade 
they are classified in well differentiated thyroid carcinoma (WDTC), in turn 
subdivided in papillary thyroid carcinoma (PTC, 80%) and follicular thyroid 
carcinoma (FTC, 10%), poorly differentiated thyroid carcinoma (PDTC, 3%) 
and anaplastic or undifferentiated thyroid carcinoma (ATC, 2%) (Wu et al. 
2014; Wells and Santoro 2014; Puxeddu et al. 2009; Shi et al. 2016).  
 PTC is often diagnosed in the 5th decade of life presenting with a slow-
growing thyroid mass. Patients usually have a palpable nodule in absence of 
any other clinical findings (Puxeddu et al. 2009). PTC is associated to an 
overall favorable prognosis; tumor recurrence and distant metastases, indeed, 
are a rare event, found in about 10% of the PTC cases (Romitti et al. 2013; Shi 
et al. 2016). PTC is characterized by specific nuclear features and typical 
papillary architecture; several PTC variants are described, including solid-
follicular, follicular, and tall-cell (Shi et al. 2016). These variants have 
different pathological features and clinical outcomes (DeLellis, 2006). 
Generally, PTCs metastasize to the local lymph nodal stations and feature a 
survival rate greater than 90% (Schlumberger 1998; Sherman 2003).  FTC is 
defined as a carcinoma with follicular cell differentiation in the absence of the 
nuclear features typical of PTC (DeLellis, 2006). FTCs are generally unifocal 
(Passler et al. 2004). Both PTCs and FTCs retain the capacity to accumulate 
and metabolize iodine (Petrulea et al. 2015).  
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 Poorly differentiated carcinomas are a subset of thyroid tumors 
considered morphologically and clinically intermediate between WDTC and 
ATC; PDTC are more aggressive than DTC but less than ATC (Burman 2014; 
Landa et al. 2016; Volante et al. 2007). Finally, the most aggressive thyroid 
tumor is represented by ATC. Although ATC is quite rare, occurring in about 
2% of thyroid tumors, it represents the first cause of death for thyroid cancer 
with the median survival time after diagnosis of about one year. ATC can 
originate de novo or represent an advanced stage of WDTC (Romitti et al. 
2013). Morphologically, it is defined as a malignant tumor composed by 
undifferentiated cells with high mitotic rate and massive stroma infiltration 
(DeLellis 2006; Smallridge et al. 2012) (Figure 1).  
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1.2 Molecular genetics of thyroid cancer 
 
  Research conducted in the last 20 years has improved our knowledge 
of the genetic alterations involved in thyroid tumorigenesis and distinct 
molecular mechanisms, specific for the vary histopatological subtypes have 
been identified (Nikiforov et al. 2011; Xing 2013; Wells and Santoro 2014) 
(Figure 1).  
 
 
 
Figure 1. Subtypes of thyroid cancers arising from parafollicular or follicular 
cells and their related oncogenic lesions.  
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 REarranged during Transfection (RET) gene activating point mutations 
have been identified in 98% of hereditary MTC and in about 50% of sporadic 
MTC cases (Wells et al. 2013; Wells et al. 2015). RET encodes a receptor 
tyrosine kinase for neurotrophic growth factors of the GDNF family (Santoro 
and Carlomagno 2013). In MEN 2A, the most frequent mutation affect 
Cysteine 634, located in the extracellular protein domain. In MEN 2B as well 
as in sporadic MTCs, the predominant RET mutation is the substitution of the 
Metionine 918 with a Threonine residue, within the tyrosine kinase domain of 
the receptor (Fallahi et al. 2014; Wells et al. 2015). Recently, RAS somatic 
mutations have been found in RET-negative sporadic MTCs (Agrawal et al. 
2013). Of note (see also below), the aberrant activation of RAS pathway is a 
common event in thyroid tumorigenesis, being present in different thyroid 
tumor subtypes such as MTCs, WDTCs, PDTCs and ATCs. RET gene 
rearrangements, commonly caused by paracentric inversions of the long arm of 
chromosome 10, are found in PTC, particularly in radiation-associated cases 
(Nikiforov et al. 2004; Ricarte-Filho et al. 2013; Cancer Genome Atlas, 2014; 
Giordano, 2016). These rearrangements generate chimeric proteins called 
“RET/PTC” all resulting in an in frame fusion of the 3' portion of RET gene 
(coding for the tyrosine kinase domain) with the 5'-terminal sequence of 
unrelated genes. These gene fusions lead to a consititutive RET kinase ligand 
independent activation which in turn induces cell transformation mainly 
through the RAS/MAPK and PI3K/AKT pathways, but also through other 
signaling cascades such as Janus kinase-1 (JAK)/signal transducer and 
activation factor (STAT), protein kinase C (PKC), sarcoma kinase (SRC), focal 
adhesion kinase (FAK) or β-catenin pathways (Mulligan, 2014).  
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Several different RET/PTC rearrangements have been identified, with 
RET/PTC1 (where the RET fusion partner is coiled-coil domain containing 
gene 6 [CCDC6], formerly known as H4) and RET/PTC3 (where the RET 
fusion partner is nuclear receptor coactivator gene 4 [NCOA4], formerly 
known as RFG/ELE1) as the most common ones (Wells and Santoro 2014; 
Fallahi et al. 2015; Nikiforov et al. 2011). Moreover, in 2-15% of PTCs 
another chromosomal rearrangement involves the Nerve Growth Factor (NGF) 
receptor (Neurotrophic Receptor-Tyrosine Kinase1-NTRK1) gene or other 
RTKS (Greco et al. 2010, Nikiforov et al. 2011; Cancer Genome Atlas, 2014). 
Noteworthy, RET gene rearrangements initially thought to be PTC-specific 
have more recently been described also in other tumor types, including lung 
adenocarcinomas, colon carcinoma, chronic myelomonocytic leukemias and 
Spitz nevi (Santoro and Carlomagno 2013). 
 Gain of function mutations of RAS genes primarily affect codons 12, 
13 and 61, with KRAS (24%) being the most common mutated member in 
follicular-cell derived thyroid carcinomas, followed by NRAS (8%) and HRAS 
(4%) (Alonso-Gordoa et al. 2015). RAS proteins are small GTP-ases belonging 
to the mitogen activated protein kinase (MAPK) pathway. RAS mutations are 
common in FTC, PDTC, ATC as well as in PTC belonging to the follicular 
variant subtype (Volante et al. 2007; Landa et al. 2016; Cancer Genome Atlas, 
2014). RAS mutations have been described to occur also in thyroid benign 
follicular adenomas (FAs), though their prevalence in benign lesions appears to 
be lower (Nikiforov et al. 2011). 
 In FTC cases negative for RAS gene mutations, chimeric proteins have 
been detected (in about 30-40% of cases) which can be more rarely (2-13%) 
found also in FAs (Durante et al. 2015).  
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These rearrangements result in the fusion of the thyroid-specific transcription 
factor paired box8 (PAX8) with the nuclear-hormone-receptor Peroxisome 
Proliferator Activated Receptor γ (PPARγ) (Raman et al. 2014; Fallahi et al. 
2015; Alonso-Gordoa et al. 2015). The resulting protein acts as a PPARγ 
dominant negative mutant and displays its oncogenic properties thought the 
activation of MAPK, transforming growth factor β (TGFβ), Wnt/β-catenin 
pathways and through the inhibition of phosphatase and tensin homolog 
(PTEN) [Raman et al. 2014].  
 The Serine/Threonine kinase BRAF, another member of the MAPK 
pathway, is also frequently deregulated in thyroid carcinomas particularly in 
PTC, tall cell variant PTC and in undifferentiated tumors. BRAF mutation is 
considered a negative prognostic marker (Elisei et al. 2008; Basolo et al. 2010; 
Xing et al. 2013; Puxeddu et al. 2014; Xing et al. 2015; Collet et al. 2016). 
Valine to Glutamic acid substitution at residue 600 is the most frequent point 
mutation of BRAF, occuring in 45% of PTCs, 10-20% of PDTCs and 20% of 
ATC (Fallahi et al. 2015). Other oncogenic BRAF mutations have been 
described, including Lysine 601 to Glutamic acid substitution (K601E), 
commonly found in follicular variant PTCs (FV-PTCs), and several small 
deletions or insertions (indels) around codon 600 (Moretti et al. 2006; Moretti 
et al. 2009; Cancer Genome Atlas 2014). Finally, rearrangements such as the 
AKAP9/BRAF one, can be found in PTC and other thyroid cancers (Ciampi et 
al. 2005; Landa et al. 2016). BRAF mutations have been associated with tumor 
recurrence caused by increase in proinflammatory state, with the degradation 
of nuclear factor kB (NF-kB) inhibitor (IkB) [Zou et al. 2015; Ferrari et al. 
2015; Alonso-Gordoa et al. 2015], combined with the downregulation of CD8+ 
cytotoxic T-cell caused by an increased expression of programmed death 
ligand 1 (PD-L1) [Brauner et al. 2016].  
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Moreover, BRAF oncogenic activation induces a radioiodine-refractory state 
associated to decreased expression of the sodium/iodine symporter (NIS), 
thyroglobulin, thyroperoxidase (TPO) and glucose transporter type 1 (Glut-1), 
secondary overexpression of vascular endothelial growth factor receptor 
(VEGFR) or hepatocyte growth factor receptor (MET) [Durante et al. 2007; 
Zou et al. 2015; Ferrari et al. 2015; Alonso-Gordoa et al. 2015], and exportin 
cellular apoptosis susceptibility (CAS) [Holzer et al. 2016]. Consistently, 
Knauf and colleagues (2005) have demonstrated that transgenic mice carrying 
BRAF V600E developed a thyroid carcinomas closely related to human PTC, 
and that these tumors rapidly progressed to PDTCs or ATCs.  
  Genetic alterations in phosphatidylinositol 3-kinase (PI3K)/AKT 
pathway are also common in thyroid carcinoma, particularly in less 
differentiated tumor types and ATC (Xing 2013). Indeed, aberrant activation of 
PI3K/AKT pathway is related with progressive dedifferentiation and 
acquisition of new genetic alterations. The PI3K/AKT oncogenic activation 
may be linked to different genetic alterations, such as mutations of the catalytic 
subunit of PI3K (PIK3CA) [12-23% ATCs, 2% PTCs and 10% FTCs], as well 
as PIK3CA amplifications (38-61% ATCs) [Garcia-Rostan et al. 2005; Xing 
2013; Romitti et al. 2012], AKT mutations (such as E17K), loss of PTEN 
through point mutations or gene silencing, and phosphoinositide-dependent 
kinase 1 (PDK1) gene amplification (Ricarte-Filho et al. 2009; Xing 2013; 
Alonso-Gordoa et al. 2015; Robbins and Hague 2016). Overexpression of 
angiopoietin-2, VEGF/VEGFR, HGF/c-MET, EGF/EGFR, PDGF/PDGFR, 
FGF/FGFR, hypoxia-inducible factor 1α (HIF-1α), among the others, have 
been correlated with thyroid tumor aggressiveness.  
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Recently, mutations in anaplastic lymphoma kinase (ALK) (Kelly et al. 2014) 
and mutations of the telomerase reverse transcriptase promoter (TERT) have 
been reported in ATCs or other less differentiated thyroid cancers (Wells and 
Santoro 2014; Melo et al. 2015; Carneiro et al. 2015; Lennon et al. 2016; 
Tavares et al. 2016). In addition, loss of function of p53 tumor suppressor gene 
and point mutation in exon 3 of the cadherin-associated protein β1 (CTNNB1) 
gene encoding β-catenin were related to ATC (Malaguarnera et al. 2007; 
Garcia-Rostan et al. 2001; Landa et al. 2016). 
 Most of these evidence point to a crucial role of two major signaling 
cascades, the MAPK and the PI3K/AKT ones, in thyroid cancer formation and 
progression (Figure 2). 
  20 
 
 
Figure 2. The main oncogenic pathways in thyroid cancer. The figure summarizes 
the most important signaling nodes as well as their cross-talks (dashed lines).  
 
 Recently, Wu et al. (2014) through biomedical literature text mining 
have generated an in silico molecular profiling of thyroid cancers, and found 
that, in fact, RAS/MAPK and PI3K/AKT pathways, together with WNT/β-
catenin and NFkB ones are the best described oncogenic pathways 
compromised in all thyroid cancers subtypes (Table 1).  
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Table1.  Top 4 related pathways and text-mining study for each subtype. 
 
 
 
 
Table 1: The reported numbers are PubMed Identifier (PMID) evidence analyzed by 
Wu et al. (2014). N/A: Not Applicable: no evidence in literature.    
 
 
 
 
 
1.3 Targeted therapy for thyroid cancer  
 
  Standard treatment for thyroid cancer is based on thyroidectomy and 
thyroid stimulating hormone (TSH) suppression, followed by radio-iodine 
ablation to remove residual disease. Despite an overall good prognosis, subsets 
of patients (about 5%) develop metastatic disease that is refractory to treatment 
(Puxeddu et al. 2011; Xing et al. 2013; Frampton 2016). For these patients no 
effective systemic therapies are available and therefore a leading 
pharmaceutical interest has been to develop specific personalized treatments 
based on the identification of “druggable targets” (Smith and Nucera 2015). 
Thus, among the novel therapeutic approaches, targeting oncogenic protein 
kinases has emerged as promising strategy in different human cancers (Muller 
et al. 2015).  
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Effectiveness of kinase inhibitors as cancers targeting agents is linked to the 
concept of “oncogene addition” (Weinstein and Joe 2008), whereby single 
constitutive activated protein may maintain cells malignant phenotype causing 
a selective dependence of cancer cells on the function of that specific protein. 
The prototypic example of these targeted drugs has been imatinib mesylate 
(Gleevec), the first kinase inhibitor approved by FDA for chronic myeloid 
leukemia (CML) in 2001 (Druker et al. 1996; Tsai and Nussinov 2013), 
followed by gefitinib (Iressa) and erlotinib (Tarceva), targeting the EGFR in 
non–small cell lung carcinomas (NSCLCs) [Yoishida et al. 2013]. In humans 
there are 518 different protein kinases, and they still represent the preferred 
targeted molecules because of their implication in a wide set of crucial cellular 
events and because of their well characterized (and conserved) activation 
mechanisms (Manning at al. 2002). 
 During the last decade, thyroid cancer therapy research has led to 
development of several drugs against different kinases. Many efforts are still 
needed to improve selectivity avoiding off-target effects on normal kinases and 
to enhance their specific antitumor effects, such as in the case of RET TKIs for 
instance (Newton et al. 2016; Frett et al. 2014; Frett et al. 2015). Among 
successful examples of the use of TKIs in thyroid cancer, there are multikinase 
inhibitors (Sorafenib, Cabozantinib, Lenvantinib, Sunitinib), BRAF inhibitors 
(Vemurafenib), tyrosine kinase inhibitor (TKI) [Vandetanib, Pazopatinib], and 
PI3K/AKT/mTOR inhibitors (Everolimus, Rapamicin, Tersirolimus); some of 
these drugs have been registered for the treatment of specific types of thyroid 
cancer (Frampton 2012; Frampton 2016). 
 Additional approaches for thyroid cancer may be redifferentiation 
agents with the aim of increasing expression of thyroid-specific differentiation 
markers leading to rescue of radioiodine sensititivity.  
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PPARγ inhibitor Rosiglitazone and HDAC inhibitor Vorinosat, for example, 
belong to this category of compounds. Importantly, inhibition of protein 
kinases acting downstream driving oncoproteins, such as with MEK inhibitor 
Selumetinib, has demonstrated the possibility not only of restraining tumor 
growth but also of rescuing radioiodine concentration (Ho et al. 2013; Wells 
and Santoro 2014; Alonso-Gordoa et al. 2015; Ferrari et al. 2015; Ruan et al. 
2015). All these drugs proved beneficial outcomes in ongoing phase II trials.  
 In tumors, it is unlikely that a single targeting drug can elicit a complete 
remission; this is because the existence of many signaling feedback loops and 
multiple interconnections of signaling transduction networks that can allow 
cancer cells to bypass the block determined by a single targeting agent, raising 
a compensatory activation of a different oncogenic pathway (Mendoza et al. 
2011). These evidence have pushed scientists to search for the possibility of 
targeting different nodes of the same pathway, and crucial core components of 
signaling transduction networks moving from a “linear signal modular scheme” 
to a “complex transduction circuit” (Kolch at al. 2015). Consistently, for 
example cross-influence between oncogenic pathways, in particular the 
mitogenic RAS/MAPK and the survival PI3K/AKT ones have been described 
(Zimmermann and Moelling 1999; Rommel et al. 1999; Aksamitiene et al. 
2010; Paraiso et al. 2010; Mendoza et al. 2011). Just as examples, c-MET 
overexpression was found to mediate reactivation of PI3K/AKT signaling in 
thyroid cancer cell lines harboring BRAF mutation (Byeon et al. 2015), and 
TSH was described to overcome BRAF V600E-induced senescence [oncogene 
induced senescence (OIS)] promoting thyroid tumor progression via AKT 
overactivation and p53 expression loss (Zou et al. 2015). 
 In this context, this dissertation has focused on the characterization of a 
novel signaling hub connecting the MAPK signaling cascade and a specific 
tyrosine kinase receptor of the EPH family.   
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1.4 EPH receptors and ephrins 
 
  
 Since the cloning of the first EPH gene in 1987 (Hirai et al. 1987) and 
the subsequent identification of EFN ligands (Bartley et al. 1994; Beckmann et 
al. 1994; Cheng end Flanagan 1994), EPH/EFN system has captured the 
attention of many authors for its uniqueness and its involvement in several 
physiological and pathological phenomena (Arvanitis and Davy 2008). 
Erythropoietin-producing human hepatocellular carcinoma receptors (EPH) 
were identified through a screening aimed at identifying novel kinases involved 
in cancer (Holland et al. 1997). EPH constitutes the largest subfamily of RTKs.  
Unlike other RTK ligands, EPH ligands, called “ephrins” (EPH family receptor 
interacting proteins-EFN), are non soluble, attached to the cell membrane and, 
sometimes, sequestered within extracellular matrix (ECM). Interaction between 
EPHs and their cognate ligands is mediated by cell-cell contacts and causes bi-
directional signaling into the opposing cells (Klein 1999; Noren and Pasquale 
2004; Pasquale 2010).   
 In humans there are 9 EPHs belonging to class A (EPHA1-EPHA8 and 
EPHA10) and 5 EPHs of class B (EPHB1-EPHB4 and EPHB6) on the basis of 
their sequence homology and ligands affinity (Pitulescu and Adams 2010). 
Ligands, EFNs, have also been divided in two groups: the A-subclass (ephrins 
A1-A5) that contains ligands that are anchored to the cell membrane by a 
glycosylphosphatidylinositol (GPI) linkage; the B-subclass (ephrins B1-B3) 
that contains ligands represented by transmembrane proteins with a short 
cytoplasmatic region (Figure 3).  EPHA9, EPHB5 and EFNA6 proteins have 
been identified only in the chicken (Pasquale 2004).  
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Figure 3. EPHs and EFNs structure. In EPH receptors the N-terminal extracellular 
region is composed by a ligand binding domain (LBD) followed by a cysteine rich 
domain (CRD) and two fibronectin-type III repeats (FNIII 1/2). With a single 
transmembrane domain (TMD), EPHs cross the membrane bi-layer and feature 
sequentially: a juxtamembrane (JMD), tyrosine kinase (TKD), sterile α motif (SAM) 
and a postsynaptic density-95/discs large/ zonula occludens-1 (PDZ) binding domains 
at the C-teminus. On the opposing cells, EFNAs and EFNBs have at the N-terminus an 
extracellular receptor binding domain (RBD); EFNAs are anchored to the cell 
membrane with a glycosylphosphatidyl-inositide (GPI) anchor, while EFNBs have a 
cytoplasmic tail with a C-terminal PDZ binding domain.  
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Thus, excluding EPHA4 (Takemoto et al. 2002) and EPHB2 (Himanen et al. 
2004) that can bind both A-type and B-type ligands with the same binding-
affinity, EPHAs bind A-type ligands, and EPHBs bind B-type EFNs (Kullander 
and Klein 2002; Pasquale 2004). In this complex system, despite each EPH 
binds with greater affinity its “preferred” ligand, it is described some 
EPHs/EFNs promiscuity (Pasquale 2004; Haramis and Perrakis 2006; Dai et al. 
2014) (Figure 4). Capability of EPHs to discriminate among different EFNs 
was described as being dependent by particular aminoacid interactions, but the 
precise mechanism is still poorly known (Pasquale 2004). Probably, this cross-
binding could be framework-dependent, in response to greater or lesser EFNs 
availability, and it can modulate different biological responses in different 
contexts. Ligand genes (such as EFNA1/3/5 genes on the q arm of the 
chromosome1) may exist as genetic cluster on the same chromosome (Perez 
White and Getsios 2014), supporting the possibility of a co-regulated 
expression. 
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Figure 4. EPHs/EFNs binding affinity, sequence omology and phylogenetic 
relationship.  Human receptor/ligand preferential binding is shown with the exception 
of EPHA10. The dendrogram was obtained by Clustal program using ligands- or 
receptor-binding domain sequences respectively  (The image is a modified version of 
Pasquale 2004). 
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 Receptor-ligand binding induces a conformational reorganization of 
EPH LBD that facilitates the interaction with other EPHs, which creates 
complementary interaction surfaces that causes the laterally joining of different 
dimer pairs into tetrameric and high-order cluster complexes. This “seeding 
mechanism” provides a model for how EFNs low level can trigger cluster 
formation and also result in oligomers but also heterodimers formation 
(Seiradake et al. 2010). Recent findings demonstrated that heterodimers of 
different EPHs can form, thus recruiting also EPHs that have not been targeted 
by the cognate EFN. Examples are EPHB6-mediated suppression of EPHA2 
signaling in breast cancer cell (Fox and Kandpal 2011) or EPHA7-mediated 
inhibition of EPHA2 signaling in lymphoma (Oricchio et al. 2011).  
 EPH/EFN are among the oldest evolutionarily conserved 
receptor/ligand pairs (Jones et al 1997). The EPH/EFN system is present also 
in Caenorabditis elegans, where at variance from vertebrates, there is only one 
EPH gene called variable abnormal-1 (VAB-1), and four EFN genes (Chin-
Sang et al. 1999; Wang et al. 1999).  
 Wykosky and Debinsky (2008) have reported the existence of a 
functional and soluble unclustered monomeric EFNA1, believed to derive from 
a proteolytical cleavage. EFNA1 was found to promote or inhibit growth 
depending on its soluble or membrane-bound state (Alford et al. 2010). 
Supporting this finding, EFNA1 and its cleaved products was found in serum 
of tumor patients, as serum biomarkers of tumor burden (Beauchamp and 
Debinsky 2012).  
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 One of the first EPH/EFN function discovered was in axon guidance; 
however, this system is nowadays regarded to as an universal cell-to-cell 
communication pathway that allows cells moving to a specific position and that 
maintains cellular organization by preventing cell intermingling through 
chemotatic/chemorepulsive forces (Holmberg et al. 2000; Pasquale 2008; 
Genander 2012). EPH receptors and EFNs are expressed in all embryonic germ 
layers in all vertebrates, and mediate cell migration and positioning, boundary 
formation and segmentation during important developmental processes such as 
gastrulation (Lisabeth et al. 2013; Park and Lee 2015). Recently, Xavier and 
colleagues (2016) reported another example of this concept, showing 
EPHs/EFNs regionally-restricted expression in palate and tongue development, 
pointing to a fine temporal and spatial-coordinated expression during tissue 
development. Furthermore, recent insights are focusing on the role of 
EPH/EFN system in the regulation of adult stem niche in various organs 
(Genander 2012; Perez White and Getsios 2014) as well as in adult organs 
specialized functions, such as synaptic plasticity, memory formation, epithelial 
and vascular homeostasis and integrity, bone remodeling, insulin secretion, 
inflammatory and immune-response (Kullander and Klein 2002; Gucciardo et 
al. 2014; Dines and Lamprecht 2015). EPHs/EFNs redundancy and gradient, 
context-dependent signaling, directionality and intensity of the interactions 
probably define organs and tissue specific outcomes (Fox et al. 1995; Muñoz et 
al. 2005).  
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1.5 EPH/EFN signaling  
 
 EPH/EFN signaling system has several important differences with 
respect to other canonical ligand/RTK signaling pairs. A unique feature of 
EFN/EPH system relies in the binding step between ligands and receptors. In 
most of the cases, EPH ligands are bound to surface of neighboring cells rather 
than freely soluble. Therefore, EPH/EFN interaction elicits “ligand dependent” 
signal activation in both ephrins- and receptor-expressing cells. In ligand-
expressing cells, binding stimulates a “reverse signaling”. In this case, EFNAs 
through their GPI-anchors exert lipid-raft mediated binding with other 
juxtamembrane proteins (such as Src family kinase), or are able to interacting 
with membrane-bound receptors such as RET or NTRK1 (Lisabeth et al. 
2013). Similarly, EFNBs are phsophorylated by Src family kinases, this in turn 
mediating association to SH2 containing protein adaptors such as Grb4 
(Lisabeth et al. 2013). Binding of PDZ contianing proteins to the PDZ-binding 
domain of EFNBs can also elicit different intracellular responses, such as 
angiogenesis, axon guidance and synaptic plasticity. 
 At the same time EFN binding to cognate EPHs elicits a “forward 
signaling” in the EPH-expressing cell (Pasquale, 2008; Lisabeth et al. 2013). 
Like all the other RTKs, EPH dimerization/oligomerization mediated by EFN 
binding is followed by conformational changes that trigger the 
autophosphorylation of the receptor on tyrosine residues; in turn, 
phosphorylation of tyrosines located into the inhibitory juxtamembrane 
receptor domain facilitate receptor activation and binding and phosphorylation 
of cytoplasmic downstream signal proteins (Binns et al. 2000; Wybenga-Groot 
et al. 2001; Davis et al. 2009).  
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EPHs also contain an autophosphorylated tyrosine residue within their 
activation loop; however, differently from other RTKs phosphorylation of this 
residue does not seem essential for kinase activity (Lisabeth et al. 2013). 
 Several autophosphorylated tyrosine residues in activated EPHs have 
been identified and involved in forward signaling. Important effectors are 
represented by Rho-like small GTP-ases as well as signal transducers typically 
activated by several RTKs such as RAS/MAPK and PI3K/AKT components 
(Figure 5). A striking difference with other RTKs is that typically EPHs use 
these mechanisms to inhibit rather than promote cell growth and to favor cell 
repulsion rather than cell attraction, this resulting at the end in tumor 
suppression rather than promotion (Miao et al. 2000; Barquilla and Pasquale 
2015; Lisabeth et al. 2013). This notwithstanding, “ligand-independent” EPH 
signaling mechanisms exist that confer to these receptors also important tumor 
promoting effects. 
 EPH impact on cell cytoskeleton and cell shape is mediated by 
regulation of Rho-family GTP-ases. The typical cell repulsive effect of several 
EPHs is, indeed, mediated by an increased balance of RhoA activation vs 
Rac1/Cdc42 activation thereby resulting in increased formation of actin 
structures named stress fibers, cell process retraction and inhibition of cell 
movement. In different conditions, however, EPHs can also promote Rac1 
activation by activating Rac1 GEF such as Vav and inhibiting RhoA via 
p190RhoGAP (Wakayama et al. 2011). 
 At a variance from most common RTKs that signal through 
RAS/MAPK pathway, EPHs frequently inhibit this signaling system and 
oppose the activity of other RTKs, such as FGFR, TRKB and IGF1R (Miao et 
al. 2001; Pasquale 2008).  
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A mechanism mediating such inhibitory function involves recruitment to EPHs 
of p120RAS-GAP that promotes GTP hydrolysis and therefore switch-off p21 
RAS (Minami et al. 2011; Pasquale 2008; Pasquale 2010). However, it is worth 
mentioning that in other cases EPHs, similarly to other RTKs, can promote 
rather than suppress RAS/MAPK signaling. In turn, a feedback loop exists so 
that MAPK signaling promotes expression of EPHA2 (Macrae et al. 2005). 
 As in the case of RAS/MAPK cascade, also another signaling cascade 
that is commonly activated by RTKs, e.g. the PI3K/AKT one, is blunted rather 
than promoted by EPH forward signaling. For instance, in several cell types 
EPHA2 stimulation reduces AKT phosphorylation on both T308 and S473 sites 
(Miao et al. 2009). Also in this case, this peculiar inhibitory activity can be 
mediated by recruitment to EPH of a negative regulator of the pathway such as 
a phosphatase. Also in this case, however, evidence exists that EPH may also 
promote rather than inhibit AKT (Figure 5). 
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Figure 5. EPH/EFN signaling. The image summarizes EFNs-mediated reverse 
signaling and EPHs-mediated forward signaling events. 
  
 
 Processing of EPH receptors upon EFN binding seems to be an integral 
part of the signal transduction mechanisms. Protease-cleavage by 
transmembrane disintegrin [such as A Disintegrin And Metalloproteinases 
(ADAMs)] or other membrane metalloproteinases (MMP-1, -2, -9, 13) 
mediates an EPH/EFN irreversible internalization (Atapattu et al. 2014). 
Receptor/ligand complexes can be internalized in either EFN- or EPH-
expressing cells through a clathrin-dependent mechanism of endocytosis 
termed transendocytosis.  
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This process is critical for cell separation and repulsive effects (Lisabeth et al. 
2013). In endosomes, part of transendocytosed EPHA2 interacts through its 
juxtamembrane domain with Rho family GEF TIAM1 thus leading to Rac1 
(and probably also RhoA/Cdc42) activation. EPHs ubiquitination and 
degradation were described also to be c-Cbl independent and dependent on the 
Src-like adaptor protein (SLAP) (Naudin et al. 2014; Boissier et al. 2013; 
Wybenga-Groot and McGlade 2015). An antagonist of EPH/EFN 
internalization is the SH2-containing 5'-inositol phosphatase 2 (SHIP2) that is 
recruited to EPHA2 through SAM domain-mediated interactions. This lipid 
phosphatase blocks EPH endocytosis via a PI3K-dependent Rac activation 
(Zhuang at al. 2007). High SHIP2 levels are involved in EPHA2 
overexpression in many cancer types. Similarly, low-molecular weight 
phophotyrosine phosphatase (LMW-PTP) that is activated by Src and 
commonly upregulated in cancer, mediates EPH receptor dephosphorylation 
and in turn decreased binding to Cbl and decreased EPH turnover (Kikawa et 
al. 2002).  
 
 
 
1.6 EPHA2 receptor in human cancer 
 
 Considering the multiplicity and the versatility played in adult and 
embryonic cellular activities, it is not surprising that EPHs/EFNs play a key 
role also in tumors (Pasquale 2008). Next generation sequencing efforts have 
identified somatic mutations in several EPH members, particularly in 
melanoma and in lung cancer. Functional implication of these mutations is still 
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largely unknown, however in most of the cases mutations are scattered 
throughout the protein sequence making unlikely a gain-of-function effect.  
In the case of one particular receptor, EPHA3, mutations identified in cancer 
have been found to disrupt ligand binding and therefore probably able to 
interfere with a ligand-dependent tumor suppressive effect of EPHA3 (Lisabeth 
et al. 2013). Other EPHA family members including EPHA2 do not seem to be 
frequently mutated in cancer and therefore their deregulation can take place at 
the transcriptional or post-translational levels. 
 Controversial tumor-suppressive or tumor-promoting roles have been 
described for several EPH members. Most of the reports point to a tumor 
suppressive effect of ligand-dependent EPH stimulation compared to an 
oncogenic effect of ligand-indipendent stimulation (Lisabeth et al. 2013). 
Accordingly, in several cancer types it is often documented a reduced 
expression of the EFN ligands and at the same time an upregulated expression 
of the EPH receptors. EPHA2 is the EPH family member most commonly 
upregulated in human cancer. EPHA2 is overexpressed in a variety of human 
malignancies and it is often associated to increased tumor grade and poor 
prognosis in diverse cancer types as breast, lung, prostate, skin, esophageal, 
gastric and renal carcinoma (Amato et al. 2014; Brantley-Sieders et al. 2008; 
Hafaner et al. 2006; Hatano et al. 2005; Herath et al. 2006; Kinch et al. 2003; 
Miyazaki et al. 2003; Nakamura et al. 2005; Walker-Daniels et al. 1999; Xu et 
al. 2014; Zelinski et al. 2001), as well as in thyroid carcinomas. 
 As far as thyroid carcinomas, Karidis and co-workers have assessed 
EPHA2 and EPHA4 protein expression by immunohistochemistry in 131 
patients with benign and malignant thyroid lesions and found a significant 
upregulation of EPHA2 in malignant lesions and in particular in papillary 
carcinomas. In contrast, EPHA4 expression was not changed in malignant 
versus benign thyroid lesions (Karidis et al. 2011).  
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O'Malley and colligues reported EPHA2 overexpression in thyroid cancer cell 
lines and in benign and malignant human thyroid tumors with respect to normal 
thyroid.  
In FTC-238 cell line, EPHA2 knock-down reduced invasion and AKT 
phosphorylation and the opposite was found upon EPHA2 overexpression in 
the FTC-133 cell line (O'Malley et al. 2012). 
 
 
1.7 EPHA2 receptor signaling  
 
 Several tyrosine autophosphorylation sites have been identified in 
EPHA2 and in some cases their role elucidated (Figure 6). Phosphorylated 
Tyr587 and Tyr593 in the EPHA2 juxtamembrane domain bind to Vav2 and 
Vav3 guanine nucleotide exchange factors, that are able to mediate up-
regulation of GTP-bound activated Rac1 GTPase (Fang et al. 2008). 
Phosphorylated Tyr735 in the N-terminal lobe of the EPHA2 kinase is able to 
bind to the p85 regulatory subunit of phosphatidylinositol 3-kinase (Fang et al. 
2008). Phosphorylated Tyr930 in the SAM domain of EPHA2 is involved in 
the binding to the Nck adaptor and its phosphorylation is negatively controlled 
by the LAR phosphatase, thereby attenuating EPHA2-mediated cell migration  
(Lee et al. 2013). SHIP2 (Src homology 2 domain-containing phosphoinositide 
5-phosphatase 2) instead is recruited to activated EPHA2 via a 
phosphotyrosine-independent mechanism involving a SAM-SAM domain 
interaction, and this reduces EPHA2 internalization (Zhuang et al. 2007) 
(Figure 6). 
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Figure 6.  Main EPHA2 tyrosine phosphorylation sites and their role in forward 
signaling.     
 
 
 Despite this detailed biochemical knowledge, output of EPHA2 
signaling in cells and in particular cancer cells is still largely unknown. EPHA2 
seems to play an important role in cell-cell contacts (Zantek et al. 1999) and 
EPHA2-mediated phosphorylation of Claudin-4 at the tight junctions decreases 
cell-cell contact enhancing paracellular permeability (Tanaka et al. 2005).  
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 In some cases, EPH signaling intersects other RTKs through 
downstream mediators or through direct interactions. Ligand-activated EPHA2 
decreases MAPK signaling (Parri at al. 2005), whereas MAPK activity leads to 
EPHA2 overexpression (Macrae et al. 2005). There is also evidence of 
EPHA2-EGFR physical and functional interaction. EPHA2 is an EGF/EGFR 
transcriptional target gene mediated by MAPK activation, and EPHA2-EGFR 
colocalize and interact at the plasmamembrane of cancer cells. EPHA2 has 
ligand-independent effects on EGF-induced cancer cell motility whereas 
EFNA1 stimulation leads to inhibition of EGF-induced motility, leading to 
EPHA2 receptor internalization, downregulation and termination of EPHA2 
positive effects on cell motility (Larsen et al. 2010). EFNA1 is a tumor 
necrosis factor α (TNFα) induced gene in human umbilical vein endothelial 
cells (HUVECs) (Holzman et al. 1990). EFNA1 expression is low in tumor 
cells but high in endothelial cells (Ogawa et al. 2000), where it acts as 
chemoattractant for other endothelial cells (Pandey et al. 1995). EFNA1 and 
EPHA2 expression are upregulated in hypoxic conditions by HIF-1α and 
VEGFR, leading to EPHA2 phosphorylation (Yamashita et al. 2008; Cheng et 
al. 2003), that in turn induces VEGFR expression (Beauchamp and Debinsky 
2012). Angiostatic Slit2 protein impairs this mechanism (Youngblood et al. 
2015).  
 A wealth of evidence points to a tyrosine phosphorylation- and ligand-
independent role of EPHA2 in promoting tumor formation (Figure 7). Despite 
its high expression levels, tyrosine phosphorylation of EPHA2 is often 
downregulated in malignant cells compared to normal cells (Pasquale et al. 
2010). EFNA1 is often lost in tumor cells and this contributes to the loss of 
cell-cell contact among cancer cells. One phosphotyrosine- and ligand-
independent role of EPHA2 has been related to the phosphorylation of a 
particular serine residue, Serine 897 (Ser897).  
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Ser897 maps in the EPHA2 SAM domain, and its phosphorylation has been 
reported to mediate the switch from an anti-oncogenic to a pro-oncogenic role 
of EPHA2 (Figure 7). 
 
 
 
Figure 7.  EPHA2 ligand dependent and independent pathway. After cell-cell 
adhesion, EPHA2/EFNA1 interaction mediates kinase activation and increased 
phospho-tyrosine content; this results in suppression of tumorigenesis. In contrast, 
ligand-unbound receptor upon Ser897 phosphorylation is able to emanate pro-
oncogenic signals.   
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Miao and coworkers demonstrated that Ser897 EPHA2 phosphorylation 
mediated by AKT is crucial for glioma and prostate cancer cell invasive 
phenotype and stem cell properties (Miao et al. 2009; 2015). S897A mutation 
abolished such a ligand-independent promotion of cell motility. In contrast, 
EFNA1 stimulation of EPHA2 blunted AKT and caused EPHA2 
dephosphorylation on Ser897 (Miao et al. 2009). Moreover, EPHA2 was 
highly expressed in glioblastoma cell lines and promoted invasion. These 
effects required AKT-mediated phosphorylation on Ser897 and did not require 
EFN binding. Importantly, EFN-null mice featured significantly increased 
glioblastoma cell invasion. Finally, overexpression of EPHA2 promoted stem 
cell properties in a kinase-independent manner (Miao et al. 2015). 
More recently, Zhou and coworkers reported that inflammatory 
cytokines are able to promote phosphorylation of EPHA2 at Ser897 mediated 
by the RSK kinase and this fosters breast cancer cells metastatic properties. 
Ser897-phosphorylated EPHA2 co-localized with phosphorylated active form 
of RSK in various human tumour specimens, and this double positivity was 
related to poor survival in lung cancer patients (Zhou et al. 2015). 
Prompted by these new informations, in this Dissertation we have 
explored role of EPHA2 and of its Ser897 phosphorylation in thyroid cancer. 
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2. AIM OF THE STUDY  
 
 
 In order to find novel protein kinases that may be involved in thyroid 
cancer, we have performed a small interfering RNA-based genetic screening in 
the RET/PTC1-positive TPC1 papillary thyroid cancer cell line using a siRNA 
library targeting the human kinome. We identified 14 hits whose silencing was 
able to significantly reduce the viability and the proliferation of TPC1 cells; 
most of them were active also in BRAF-mutant BCPAP (papillary thyroid 
cancer) and 8505C (anaplastic thyroid cancer) and in RAS-mutant CAL62 
(anaplastic thyroid cancer) cells. Kinases relevant for thyroid cancer cell 
viability included SRC and MAPK (mitogen activated protein kinases) families 
and importantly the EPHA2 receptor  (Cantisani et al. 2016).  
 In this framework, Aim of this study has been to understand the role of 
EPHA2 in thyroid tumorigenesis. In particular, we studied: 
 
1) expression and phosphorylation of EPHA2 in thyroid cell lines 
harboring different oncogenic lesions; 
 
2) how RET/PTC1 and BRAF V600E thyroid oncogenes influence 
EPHA2 activation; 
 
3) role and kinases involved in mediating the activatory phsophorylation 
of EPHA2 on Serine residue 897.  
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3. MATERIALS AND METHODS  
 
 
 
3.1 Cell culture  
 
 
 Thyroid cancer cells featuring different complements of genetic lesions 
were authenticated by SNP genotyping (Table 2). TPC1 and BCPAP cell 
lines were derived from PTC, while 8505C, SW1736, OCUT-1 and 
CAL62, were derived from ATC (Table 3). Nthy-ori 3-1 (hereafter referred 
to as NTHY) (ECACC, Wiltshire, UK) is a human follicular epithelial cell 
line derived from a normal thyroid tissue immortalized by SV40 large T 
gene. NTHY cells were grown in RPMI-1640 medium supplemented with 
10% FBS (Foetal Bovine Serum) (GIBCO, Paisley, USA), while all the 
other cell lines were grown in DMEM (Dulbecco’s Modified Eagle’s 
Medium) supplemented with 10% FBS, 2 mM L-glutamine and 100 U/mL 
penicillin-streptomycin (GIBCO). PC Cl 3 (hereafter referred to as PC) is 
differentiated non tumoral thyroid follicular cell line derived cells from 18-
month-old Fischer rat. PC cells were cultured in Coon’s modified HAM’s 
F12 medium (LONZA, Walkersville, USA) supplemented with 5% CS 
(calf serum) [BioWhittaker for LONZA], 2 mM L-glutamine and 100 
U/mL penicillin-streptomycin and a mixture of 6 hormones, including 
thyrotropin (10 mU/mL), hydro-cortisone (10 nM), insulin (10 µg/mL), 
apo-transferrin (5 µg/mL), somatostatin (10 ng/mL), and glycyl-histidyl-
lysine (10 ng/mL) [Sigma-Aldrich Chemie GmbH, Steinheim, DE]. Stably 
transfected PC-RET/PTC1 and BRAF V600E cells as well as Doxycycline 
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inducible RET/PTC3 cells have been described previously (Knauf et al. 
2003; Castellone et al. 2003; Wang et al. 2003).  
Transformed PC cells were grown in the absence of 6H. Phoenix human 
embryonic kidney cells (hereafter named φχ) were used for transient 
expression studies. These cells were grown in DMEM contaning 10% FBS, 
2 mM L-glutamine and 100 U/mL penicillin-streptomycin.  
 
Table 2: Authentication of the thyroid cell lines used in this study. 
 
 
 
Table 2: 24 genetic markers (PowerPlex Fusion System kit) were analysed by BMR 
Genomics s.r.l. in the indicated cell lines. 
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Table 3: Oncogenic lesions in the thyroid carcinoma cell lines used in this study. 
 
 
Table 3: The indicated mutations were derived from catalogue of somatic mutations 
in cancer (COSMIC) [www.sanger.ac.uk/genetics/CGP/cosmic/]. 
 
 
 
3.2 Cell treatments  
 
 
 Drug treatments were performed in low serum conditions (2.5% FBS or 
CS) for the indicated time points. ZD 6474 (0.25-1 µM), PLX 4032 (0.25-1 
µM), U0 126 (5 µM, Cell Signaling, Danvers, USA), BI-D1870 (0.5-1 µM, 
Selleckchem, Munich, DE), Wortmannin (0.5 µM, Cell Signaling 
Technology, Lane Danvers, USA), Doxycycline (1µg/mL, Sigma-Aldrich 
Inc., Saint Louis, USA) were used as specified.  
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3.3 Plasmids construction and expression 
 
  
 The plasmid encoding human GFP-tagged EPHA2 (RG205725) 
(GenBank accession number NM_004431) was purchased from Origene 
Technologies (Rockville, USA) and was used also as template to generate 
the EPHA2 Ser897Ala (S897A) mutant. Mutagenesis was performed by 
using the QuickChange Site-Direct mutagenesis kit (Stratagene/Agilent 
Technologies, Santa Clara, USA). Primers were designed according 
QuickChange Site-Direct mutagenesis instruction, controlled on Operon 
tool (http://www.operon.com/tools/oligo-analysis-tool.aspx), and 
synthesized by the Ceinge Core Service Unit (Naples, IT). The mutations 
were confirmed by DNA sequencing performed by Ceinge Core Service 
Unit.  Primer sequences were as follows:  
Forward: 5'-gct atc cgg ctc ccc gcc acg agc ggc tcg gag-3';  
Reverse: 5'-ctc cga gcc gct cgt ggc ggg gag ccg gat agc-3'.  
The pRK7-myr-RSK1 (8997) (GenBank accession number 
NM_001006665.1) plasmid was purchased from Addgene (Addgene, 
Cambridge, USA). Myr-AKT and HA-MEKEE (activated MEK1 generated 
by replacing Ser-218 and Ser-222 by Glutamic acid) plasmids were kind 
gifts of Professor J. Silvio Gutkind (University of California and Moores 
Cancer Center, San Diego, CA).   
 For φχ cell transient transfections, cells were plated at 50% confluence 
in 60-mm poly-D-lysine Hydrobromide (10 µg/mL); 1 µg of each plasmid 
was mixed with 10 µL of Polyfect transfection Reagent (Qiagen, Hilden, 
DE) and 100 µL of serum free DMEM, incubated for 48 h in complete 
medium and starved O/N before collection. 8505C and PC cells were 
transfected using Fugene reagent (Promega Corporation, USA).  
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RSK knock-down experiments were performed with ON-TARGETplus 
SMARTpool RSK1 (L-003025-00) and RSK2 (L-003026-00) human 
siRNA (Carlo Erba for DharmaconGE, Cornaredo, IT). EPHA2 silencing 
was performed with ON-TARGETplus SMARTpool EPHA2 (E-003116-
00). As suggested by manufacturer instructions, 10 µL of 5 µM siRNA 
were mixed with 2.5 µL of Dharmafect1 transfection reagent (Carlo Erba) 
in Optimem medium (GIBCO). The transfection mix was added at 25 nM 
final concentration and delivered to each plate for 48 h. Instead, in the 
silencing-rescue experiment, EPHA2 was knocked-down in 8505C cells 
with a human specific siRNA (SI02223508) from Qiagen and in PC rat 
cells with a rat ON-TARGETplus SMARTpool (L-099402-02) provided by 
DharmaconGE (Carlo Erba). In details, in this case, 8505C cells were 
transfected using 6.6 µL of 20 µM siRNA mixed with 200 µL of Optimem 
medium and 13.2 µL of HiPerFect Transfection reagent (Qiagen) for 10 
min. The transfection reaction was then applied at 22 nM final siRNA 
concentration to each plate. Rat EPHA2 transient knock-down was 
performed in the same conditions as described for RSK silencing in 
medium containing 5% serum. As negative controls for all our silencing 
experiments, we transfected AllStars Negative Control siRNA 
(SI03650318, Qiagen) or siGENOME Non-Targeting siRNA (D-001206-
13, Carlo Erba), as previously described. Following 36 h of silencing, 
rescue was obtained by transient transfection; this was performed by using 
EPHA2 wt (4 µg) or EPHA2 S897A mutant (7 µg) and 12 µL of Fugene 
(Promega). GFP, EPHA2 wt or EPHA2 S897A plasmids were transfected 
as control. Trypan Blue exclusion test and dosage of cleaved-PARP in 
protein lysates were applied to exclude non-specific toxicity of the 
transfection procedure (data not shown). 
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 3.4 Protein experiments  
 
 
 Cell cultures plates were washed two times with ice-cold PBS 1X 
solution (GIBCO) and cells were scraped in fresh JS lysis buffer containing 
50 mM N-2- hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES pH 
7.5), 1% (vol/vol) Triton X-100, 150 mM NaCl, 5 mM EGTA, 50 mM 
NaF, 20 mM sodium pyrophosphate, 1 mM sodium vanadate, 2 mM 
phenylmethylsulphonyl fluoride (PMSF) and 1 µg/mL aprotinin. Lysates 
were than clarified by centrifugation at 13,500 rpm for 20-30 min and kept 
at 4°C during all passages. Protein concentration was measured using a 
modified Bradford Assay (Bio-Rad Laboratories, Munich, DE). Protein 
lysates (15-50 µg) were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) and transferred on 
Whatman Protran nitrocellulose membranes (PerkinElmer Health Sciences 
B.V., Groningen, NE). For EPHA2 pull-down, after precleaning with 
gamma-bind G sepharose beads (GE Healthcare Bio-Sciences AB, 
Uppsala, SE), 500 µg of fresh cell lysates in 500 µL volume were 
incubated overnight at 4°C (with gentle rotation) with 0.1 µg of 
recombinant Human Ephrin-A1 Fc protein (R&D Systems, Minneapolis, 
USA) for 1 mg of cell lysate. Ligand-receptor complexes were pulled-down 
using 50 µL of protein-G sepharose beads for 1 h at 4°C. The samples were 
centrifuged and washed in JS buffer, eluted in sample buffer loading dye, 
boiled for 5 min at 99°C and run on 7.5% SDS-polyacrylamide gel. 
Immunoprecipitations were performed according to standard procedures. 
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After blotting, membranes were incubated in 5% non-fat dry milk (Bio-Rad 
Laboratories) or TBS containing 5% BSA (Sigma-Aldrich Inc.) blocking 
solution for 1 h at room temperature and then with primary antibodies O/N 
at 4°C. After appropriate washes, the membranes were incubated for 1 h at 
room temperature with HRP-conjugated anti-mouse or anti-rabbit 
secondary antibodies (dilution 1:3000) from Bio-Rad Laboratories, or with 
HRP-conjugated donkey anti-goat secondary antibodies (dilution 1:3000) 
from Santa Cruz Biotechnology (Heidelberg, DE). Immunocomplexes were 
detected using the enhanced chemiluminescence kit (ECL) from Thermo 
Fisher Scientific/Life technologies (Rockford, USA); images were scanned 
with Epson Perfection V750 PRO and signal intensity was acquired by 
Cawomat 2000 IR. Primary antibodies (Table 4) were from Millipore 
(Merk Millipore Corporation/Life Science, Darmstadt, DE), R&D Systems, 
Cell Signaling Technology, Santa Cruz Biotechnology, Upstate (Lake 
Placid, USA), Sigma-Aldrich. Anti-RET is a polyclonal antibody raised 
against the tyrosine kinase protein fragment of human RET (Santoro et al. 
1995).  
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Table 4: Antibodies used in this study. 
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 3.5 Phosphorylation studies  
 
 
 φχ cells transfected with EPHA2 wt plasmid were lysed without 
phosphatase inhibitors in EDTA-free JS buffer according to published 
procedure (www.abcam.com; Feng and Irvine 2009). 30 µg of crude 
extracts were treated with 1U/µg of CIP (Calf Intestinal alkaline 
Phosphatase; New England Biolabs, Beverly, USA) for 30 min at 37°C. 
The reaction was stopped by adding loading dye and heating at 99°C for 5 
min before SDS-PAGE. To verify whether RSK kinase was able to 
phosphorylate in vitro EPHA2, 200 ng of recombinant full length active 
RSK1 (R15-10G) from SignalChem (Richmond, USA) was incubated with 
20 ng of EPHA2 GST-tagged cytosolic domain (PV3688) from Thermo 
Fisher Scientific/Life technologies in kinase buffer [25 mM MOPS (pH 
7.2), 12.5 mM β-glycerophosphate, 25 mM MgCl2, 5 mM EGTA, 2 mM 
EDTA, 0.25 mM DTT and 50 µM ATP]. Following 30 °C incubation for 
15 min, the reaction was stopped by 99°C heating in loading dye for 5 min. 
De-phosphorylation was performed directly on the nitrocellulose 
membrane after in vitro phosphorylation reaction. The membrane was 
blocked with 5% BSA in TBS with 0.1% of Triton X-100 for one hour at 
room temperature and then incubated with TBS-1% Triton with or without 
CIP (68 mU/µg) for 30 min in a 37°C water-bath. Membranes were then 
incubated for 1 h with phospho-S897 EPHA2 antibody. For [32P]-ATP 
kinase assay, EPHA2 peptides spanning Serine 897 
(wt:RVSIRLPSTSGSE, S897A:RVSIRLPATSGSE, 
R894K:RVSIKLPSTSGSE, 4A: RVAIRLPSAAGAE) were synthesized by 
PolyPeptide Group Laboratories (Strasbourg, FR). Kinase assay was 
performed using 10 µM of each peptide, 100 nM of RSK1 recombinant 
kinase and 50 µM of [32P]-ATP for 15 min at 30 °C.  
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The reaction was spotted on pre-cut phosphocellulose P81 paper (Merk 
Millipore Corporation/Life Science). After several washes with 1% 
orthophosphoric acid (Carlo Erba), filters were air-dried and subjected to 
Cherenkov counting.  
 
 
 
  3.6 RNA extraction, cDNA synthesis and RT-PCR  
 
 
 For mRNA expression, each cell line was grown to 70% confluency, 
total RNA was extracted with RNeasy mini kit (Qiagen) according to the 
manufacturer’s instructions and quantized with NanoDrop 2000c (Thermo 
Fisher Scientific/Life technologies). RNA (1µg) was reverse transcribed 
(RT) using a high-capacity reverse transcriptase kit (Quantitect Reverse® 
Transcription Kit, Qiagen) according to manufacturer’s instructions. The 
mRNA level (40 ng for each cDNA) of RSK family members in thyroid 
cell lines was measured by semiquantitative RT-PCR assay using 
JumpStart REDTaq ReadyMix PCR (Sigma-Aldrich) according to 
manufacturer's instructions for 30 cycles.  The levels of the housekeeping 
GAPDH transcript were used as a control for equal cDNA loading. The 
thermal protocol was: 94° for 2 min (1 cycle), 94° for 30 sec, 60 ° for 30 
sec, 72° for 2 min (30 cycles), 72° for 5 min (1 cycle); reaction was stopped 
at 4°C. GAPDH was amplified for 25 cycles. PCR products were loaded on 
1% agarose gel, stained with ethidium bromide (0.05 µg/mL), and the 
corresponding image was saved by Bio-Rad Quantity One software 4.5.2 
(Bio-Rad Laboratories).  
To exclude DNA contamination, each PCR reaction was also performed on 
untranscribed RNAs (data not shown).  
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The primers were designed using Primer-BLAST tool (available on 
www.ncbi.nlm.nih.gov) and synthesized by the Ceinge Core Service Unit. 
The sequences of used primers were shown in Table 5. 
 
Table 5: primers sequence. 
 
 
 
 3.7 Cell proliferation assays  
 
 
 8505C cells  (4 x 105) or PC BRAF V600E (8 x 105) were plated in 60-
mm dishes. Cells were then counted 48 or 72 h after plating. Each count 
was performed in triplicate and each point was the mean value of 3 dishes 
with 95% confidence intervals. 
 
 
 
 3.8 Wound healing assay   
  
 
 8505C cells were transfected as indicated and grown for 60 h to form 
cell monolayers (80% confluency). A wound of approximately 300µm 
width was inflicted with a sterile pipette tip. The culture medium was re-
freshed to remove non-adherent cells.  
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Wound closure (healing) was monitored with microphotographs (6X 
magnification) taken with the Leica DM IL light microscope (Leica 
Microsystems, Wetzlar, DE) immediately (t0), 24 (t1) and 48 h (t2) after 
the wound in 5% serum. Experiments were performed in triplicate. 
 
 
 3.9   Statistical analysis   
 
 
Statistical analyses were performed using a paired, two-tailed Student’s t 
test (GraphPad Prism 3.0, GraphPad Software, San Diego, USA), and 
differences were considered to be statistically significant at a value of p 
≤0.05. 
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4. RESULTS 
 
 
 4.1 EPHA2 receptor is phosphorylated at Ser897 in 
thyroid cancer cell lines 
 
  
 Our previous studies, based on a genetic knock-down screening, 
indicated that EPHA2 was essential for thyroid cancer cell proliferation 
(Cantisani et al. 2016). In order to investigate further the role of the EPHA2 in 
thyroid cancer cells, we studied expression and phosphorylation of EPHA2 in a 
small panel of cell lines either harboring RET/PTC1, BRAF V600E or KRAS 
G12R point mutations (see Table 3). Normal follicular thyroid NTHY cells 
were used as control. Figure 8 shows that EPHA2 is robustly expressed in all 
the cancer cell lines tested. Moreover, while phosphorylation on the 
autocatalytic Tyrosine (Y772) was variable and not particularly intense, 
phosphorylation on Ser897 was intense and consistent throughout the cell lines. 
This was particularly interesting considering previous evidence in the literature 
pointing to a specific role of Ser897 phosphorylation in transducing 
trasforming signals in human cancer cell lines (see Introduction).  
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Figure 8. EPHA2 expression and phosphorylation in thyroid cell lines. Serum 
starved indicated cell lines were studied by Western blot analysis with the indicated 
antibodies. Actin was used for protein lysates normalization. 
 
 
 
 Then, to test whether the pSer897 antibody was specific for the 
detection of the EPHA2 Ser897 only when phosphorylated, we treated the 
lysates of embryonic kidney φχ cells transiently transfected with EPHA2 
receptor with Calf Intestinal Phosphatase (CIP) for 30 min and tested the level 
of Ser897 phosphorylation by Western blot analysis. A strong reduction of 
pSer897 reactivity was observed after CIP treatment supporting the specificity 
of the used antibody (Figure 9A). The antibody specificity was further 
confirmed by transfecting φχ cells with expressing vectors containing the wild-
type (wt) or the mutant (S897A) EPHA2. Figure 9B shows that the Alanine to 
Serine replacement impaired the antibody signal, further demonstrating 
antibody specificity.  
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Figure 9. EPHA2 pSer897 antibody test. Reactivity with pSer897 was tested in φχ 
cells transiently transfected with GFP-tagged full-length EPHA2 and treated or not 
with Calf Intestinal Phosphatase (CIP) 1U/µg (A) and in φχ cells transfected with 
GFP-tagged EPHA2 S897A mutant compared to EPHA2 wild-type (wt) (B). CTRL 
refers to mock transfected cells. Tubulin was used for normalization. 
 
 
 
 Then, we tested by Western blot the levels of the phoshorylated Ser897 
in an expanded panel of human thyroid cancer cell lines (see Table 2 and 
Table 3): BCPAP, SW1736 and OCUT-1 (harboring BRAF V600E) and 
CAL62 (harboring KRAS G12R) as well as NTHY as control. Both papillary 
(TPC1 and BCPAP) and anaplastic (8505C, SW1736, OCUT-1, CAL62) 
thyroid cell lines featured highly levels of phosphorylated Ser897 compared to 
control (Figure 10A). Noteworthy, some of the cell lines tested featured 
activating mutation (V600E) in a pure MAPK driver (BRAF) and, accordingly, 
robust and consistent phosphorylation in MEK and ERK suggesting a role of 
MAPK pathway in sustaining Ser897 phosphorylation in addition to AKT, a 
kinase that has been proposed as one of the kinases able to mediate Ser897 
phosphorylation in glioma cells (Miao et al. 2009). 
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 To confirm these findings, we used the rat-derived PC thyroid follicular 
cell line adoptively expressing Myc-tagged versions of RET/PTC1, a MAPK 
and AKT driver, or BRAF V600E, a pure MAPK driver. According to the 
capability of MAPK of stimulating EPHA2 expression (Macrae et al. 2005), 
PC-RET/PTC1 and -BRAF cells expressed high levels of EPHA2 with respect 
to parental cells. Moreover, phosphorylation at Ser897 residue was strong in 
both cell lines (Figure 10B). 
 
 
 
Figure 10. EPHA2 expression and Ser897 phosphorylation in thyroid cancer 
cells. A) The indicated thyroid cells were serum starved O/N and 15 µg of cellular 
extracts were immunoblotted with pSer897 and total EPHA2 antibodies. 
Phosphorylation of MEK (S217/S221), ERK (T202/Y204), AKT (S473) was explored 
with phosphospecific antibodies; B) Whole cell lysates (WCL) of parental PC cells 
and PC cells stably transfected with RET/PTC1 or BRAF V600E, were subjected to 
Western blot analysis for pSer897 and total EPHA2. 500 µg of cell lysates were 
immunoprecipitated (IP) with anti-tag Myc antibody and immunoblotted with pY1062 
RET (RET/PTC1) or BRAF antibodies. Tubulin levels were measured for 
normalization. These experiments are repeated at least three times. 
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 To dissociate the influence of RET/PTC-mediated EPHA2 upregulation 
from its increased phosphorylation on Ser897, a short term experiment was 
performed by using a conditional model represented by PC cells stably 
expressing another type of RET/PTC fusion (RET/PTC3 variant, e.g. the 
NCOA4-RET fusion) in a Doxycycline-inducible manner (Knauf et al. 2003). 
In this experiment, RET/PTC3 up-regulation upon Doxycyline treatment 
resulted in a gradual and time-dependent increase of Ser897 phosphorylation, 
while EPHA2 expression levels did not change significantly a these time 
points. In parallel, RET/PTC3 induced an early (12h-48h) MEK/MAPK and 
AKT activation, and a delayed (48h) activation of p90RSK, a downstream 
effector of MAPK (see below); p90RSK activation nicely paralleled S897 
phosphorylation (see below) (Figure 11). Doxycycline wash-out decreased 
MEK, MAPK and AKT phosphorylation while Ser897 and p90RSK 
phosphorylation persisted for at least 48h upon the wash-out.  
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Figure 11. EPHA2 pSer897 induction in RET/PTC3 cells. PC cells stably 
expressing a conditional RET/PTC3 construct were stimulated with 1 µg/mL 
Doxycycline in low serum conditions (1%) for the indicated time points; after 48h 
stimulation, Doxycycline was washed-out (WO) for 24 or 48h and cell lysates were 
subjected to Western blot analysis with the indicated antibodies; tubulin was used for 
normalization. These figures are representative of three different experiments. 
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 4.2 EPHA2 Ser897 phosphorylation correlates with 
 oncogene activation in thyroid cancer cell lines 
 
 
 We tested whether the pharmacological inhibition of RET and BRAF in 
cell lines expressing these activated oncogenes was able to reduce levels of 
pSer897 EPHA2. Thus, TPC1 and 8505C cells were treated for 1h with the 
indicated doses of the kinase inhibitors ZD6474 (a RET inhibitor) or PLX4032 
(a BRAF inhibitor), respectively. As shown in Figure 12A, both inhibitors 
were able to inhibit their own targets in a dose-dependent manner (as 
demonstrated by the reduced phosphorylation levels of RET, AKT, MEK and 
MAPK in the case of ZD6474, or MEK and MAPK in the case of PLX4032). 
Importantly, in parallel to MAPK pathway inhibition, both the compounds 
strongly reduced the phosphorylation of EPHA2 at Ser897; this suggested that 
a kinase in the MAPK cascade could be involved in Ser897 phosphorylation.  
 Therefore, we examined the aminoacid sequence surrounding Ser897. 
We found that Ser897 is embedded in the consensus sequence for the 
phosphorylation mediated by AGC (PKA, PKG, PKC) family kinases (Pearce 
et al. 2010). EPHA2 in particular bears a RLPS(897) sequence, with an 
Arginine residue at position -3 relative to Ser897 (Figure 12B). Accordingly, 
in thyroid cancer cells EPHA2 protein, pulled-down with recombinant EFNA1 
ligand, was recognized by a phospho-specific antibody targeting the RXXpS/T 
sequence (containing an Arginine at position -3), but not by an antibody 
targeting the RXRXXpS/T sequence (requiring also an Arginine at position -5) 
used as a control (Figure 12C). Of note, one member of the AGC family 
kinases is p90 ribosomal S6 kinase (p90RSK) is a well-known effector of the 
MAPK signaling cascade (Galan et al. 2014).  
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Indeed, p90RSK contains an effector N-terminal (NTKD) kinase domain that 
belongs to the AGC family. NTKD is linked to a C-terminal (CTKD) 
regulatory kinase domain, that instead belongs to the CaMK family (Romeo et 
al. 2012). NTKD phosphorylates substrates containing the RXXS/T consensus 
(Galan et al. 2014; Moritz et al. 2014). In details, ERKs initiate p90RSK 
activation via phosphorylation of CTKD on T573; in turn, CTKD 
phosphorylates S380 within the linker region and this primes NTKD for final 
activation mediated by PDK1 (Romeo et al. 2012). Noteworthy, p90RSK has 
been recently demonstrated to be able to phosphorylate EPHA2 on Ser897 
(Zhou et al. 2015).  
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Figure 12. EPHA2 Ser897 as a MAPK pathway target.  A) TPC1 and 8505C cells 
were treated for 1h with ZD6474 or PLX4032 at the indicated doses, and lysates were 
immunoblotted with the indicated antibodies; B) Ser897 of EPHA2 is embedded in a 
p90RSK kinase (N-terminal kinase domain: NTKD) consensus sequence; in the 
reported WebLOGO representation, bits on the ordinate axis show the relative 
relevance of the conserved aminoacids (Galan et al. 2014); C) NTHY, TPC1 and 
8505C cells underwent pull-down assay with EphrinA1-Fc; upon SDS-PAGE, the 
indicated antibodies recognizing phosphorylated RXXS/T or RXRXXS/T sequences, 
or pSer897 and EPHA2 were used. Tubulin was used as loading control (WCL). These 
experiments are repeated at least three times. 
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 4.3 p90RSK inhibition attenuates EPHA2 Ser897 
 phosphorylation in thyroid cancer cell lines 
 
 
 To dissect the signaling cascade involved in EPHA2 Ser897 
phosphorylation, RET/PTC1-positive TPC1 cells and BRAF V600E-positive 
8505C cells were treated with the ATP-competitive RET (ZD6474) or BRAF 
(PLX4032) kinase inhibitors, respectively, as well as with MEK (UO126), 
NTKD RSK (BI-D1870), or PI3K (Wortmannin) inhibitors. As expected, in 
TPC1 cells, treatment with ZD6474 abrogated the phosphorylation of the 
MAPK signaling cascade effectors (RET, MEK, MAPK, p90RSK) (Santoro 
and Carlomagno 2013), as well as effectors of the PI3K/AKT signaling 
pathway (AKT). Phosphorylation of YB1 and PRAS40 was also studied since 
YB1 is a well-known substrate of both AKT and p90RSK and PRAS40 is an 
AKT substrate (Davies et al. 2015; Wang et al. 2012). In these cells, RET 
inhibition attenuated Ser897 phosphorylation, suggesting that both MAPK and 
AKT signaling pathways concurred in the EPHA2 phosphorylation (Figure 13, 
left panel). Accordingly, in these cells both UO126 and Wortmannin treatments 
caused a significant de-phosphorylation of Ser897 (though it should be noted 
that Wortmannin also caused a reduced phosphorylation of MEK). Differently, 
in 8505C cells, PLX4032 treatment abrogated the phosphorylation of MEK, 
MAPK, p90RSK and YB1, but not AKT or PRAS40, suggesting that, in these 
cells driven by a BRAF mutation, only the MAPK pathway is involved in 
EPHA2 phosphorylation on Ser897; accordingly, Wortmannin had virtually no 
effect on Ser897 phosphorylation (Figure 13, right panel). Importantly, in both 
cell lines treatment with the p90RSK (NTKD) inhibitor (BI-D1870) strongly 
decreased Ser897 phosphorylation, in parallel to YB1 dephosphorylation 
(Figure 13). 
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Figure 13. Modulation of Ser897 EPHA2 phosphorylation in thyroid cell lines by 
different chemical inhibitors: Protein lysates (15 µg) were harvested from TPC1 or 
8505C cells treated in low serum condition with indicated doses of ZD6474, 
PLX4032, UO126, BI-D1870 or Wortmannin (Wort) for 1h. Western blots were 
probed with the indicated antibodies. Tubulin was used as loading control. These 
figures are representative of three independent experiments. 
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 Similarly, in PC-RET/PTC1 or PC-BRAF cell lines, the inhibition of 
RET and BRAF, respectively, induced a reduction of pSer897 levels, whereas 
the PI3K inhibitor Wortmannin, did not. In particular, despite the efficient 
AKT inhibition, Wortmannin showed only a modest effect on the 
phosphorylation of Ser897 in PC-RET/PTC1 and even a more modest effect in 
PC-BRAF cells (Figure 14). 
 
 
 
 
Figure 14. Modulation of Ser897 EPHA2 phosphorylation in thyroid cell lines by 
different chemical inhibitors: Protein lysates (15 µg) were harvested from 
RET/PTC1 or BRAF V600E expressing PC cells treated in low serum condition with 
indicated doses of ZD6474, PLX4032, UO126, BI-D1870 or Wortmannin (Wort) for 
1h. Western blots were probed with the indicated antibodies. The asterisk (*) indicates 
an aspecific faster migrating band identified by the p90RSK antibody. Tubulin was 
used as loading control. These figures are representative of three independent 
experiments. 
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 Finally, in agreement with these findings, BRAF, MEK and p90RSK 
inhibition in additional thyroid carcinoma cell lines (BCPAP and SW1736 
carrying BRAF V600E and CAL62 carrying KRAS G12R see Table 3) was 
able to blunt pSer897 levels, whereas Wortmannin had negligible effect 
(Figure 15). Noteworthy, in CAL62 cells, as previously described (Heidorn et 
al. 2010), BRAF inhibition caused a paradoxical activation of the MAPK 
signaling cascade rather than inhibition, probably due to the formation of active 
RAF dimers in a RAS-dependent manner; consistently, this was associated to 
increased EPHA2 pSer897 levels (Figure 15, right-end panel).  
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Figure 15. Modulation of Ser897 EPHA2 phosphorylation in a panel of thyroid 
cancer cell lines. BCPAP, SW1736 and CAL62 cells were treated with indicated 
doses of PLX4032, UO126, BI-D1870 and Wortmannin (Wort) for 1h. Drug 
treatments were performed in low serum for 1h; protein lysates were immunoblotted 
with antibodies recognizing MEK/MAPK/p90RSK pathway components (pMEK, 
pMAPK, p90RSK, pYB1) as well as AKT pathway (pAKT, pPRAS40). Levels of 
EPHA2 and pSer897 EPHA2 were tested. Tubulin was used as loading control. These 
images are representative of three independent experiments.  
 
 
 Altogether, these data showed that, in BRAF transformed cells, EPHA2 
phosphorylation at Ser897 is sustained by MAPK signaling and in particular by 
p90RSK. In RET mutant thyroid cancer cells, PI3K pathway, together with the 
MAPK pathway, may concur to mediate Ser897 phosphorylation. However, 
cell treatment with MK2206, an AKT kinase inhibitor, failed to significantly 
downmodulate Ser897 phosphorylation (data not shown) pointing against a 
crucial role of AKT in this process. 
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 4.4 p90RSK induces EPHA2 Ser897 phosphorylation 
 
 
 The above reported findings pointed to a role of MAPK system in 
EPHA2 Ser897 phosphorylation. Thus, in order to formally identify the kinase 
able to mediate EPHA2 Ser897 phosphorylation, we transfected φχ cells with 
active forms of AKT (Myr-AKT), MEK (HA-tagged MEKEE) or RSK1 (Myr-
RSK1). The full-length GFP-tagged EPHA2 and GFP alone were used 
respectively as controls, respectively. Transfection with either AKT or MEK 
and RSK induced a modest increase of endogenous EPHA2 expression. 
Besides that, it was important to observe that Myr-RSK1 expression was able 
to induce a strong potentiation of Ser897 phosphorylation. AKT and MEK 
were clearly weaker that RSK at inducing such a phosphorylation despite 
enhancing their signaling (pAKT on S473 and pERK on T202/Y204, 
respectively). It is possible that the weak activity of MEK in this system is due 
to low levels of endogenous RSK expressed in the used cell type (Figure 16). 
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Figure 16. EPHA2 and pSer897 induction. φχ cells were transiently transfected with 
GFP, GFP-EPHA2, Myr-AKT, HA-MEK-EE or Myr-RSK1 plasmids. Cell lysates (50 
µg) were starved O/N after transfection and subjected to Western blotting with the 
indicated antibodies; tubulin was used for normalization. These figures are 
representative of three different experiments. 
 
 
 We aimed at obtaining a genetic evidence of the in vivo role of p90RSK 
in mediating Ser897 phsophorylation. p90RSK family contains 4 members, 
among which p90RSK1 and p90RSK2 are the best characterized and most 
commonly involved in cancer (Sulzmaier and Ramos 2013). Initially, we 
analysed by RT-PCR the expression levels of the 4 isoforms in a panel of 
thyroid cancer cell lines. RSK1 and 2 resulted consistently expressed 
throughout the cell lines tested (Figure 17). Therefore, we performed a siRNA-
mediated knock-down experiment in 8505C cells to blunt expression of 
p90RSK1, p90RSK2 or both.  
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Results showed that the simultaneous knock-down of both p90RSK1 and 2 
significantly reduced phosphorylation of EPHA2 Ser897 as well as of YB1, a 
bona fide p90RSK substrate, while knock-down of either p90RSK1 or 
p90RSK2 alone did not significantly affect EPHA2 phosphorylation (Figure 
17). It has been previously reported that RSK1 and 2 play redundant functions 
and that therefore it is required to knock-down both to achieve a significant 
effect (Torchiaro et al. 2015). 
 
 
 
Figure 17. p90RSK as a EPHA2 Ser897 kinase. A) The mRNA levels of p90RSK1-
4 were tested by semiquantitative RT-PCR in the indicated cell lines. GAPDH was 
used for normalization; B) Silencing of endogenous EPHA2, p90RSK1, p90RSK2 or 
combination thereof was obtained by indicated siRNA (25 nM) transfection in 8505C 
cells; 48h after transfection, cells were lysed and analyzed by Western blot with 
indicated antibodies. Tubulin was used as internal control. These figures are 
representative of three different experiments. 
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 Finally, we sought to obtain the formal proof that RSK was a Ser897 
kinase. To this aim, we performed an in vitro kinase assay by using full-length 
GST-tagged recombinant p90RSK1, as a kinase, and the cytoplasmic EPHA2 
(cEPHA2) domain, as a substrate. As shown in Figure 18, when incubated 
alone, cEPHA2 showed a detectable level of reactivity with the pSer897 
antibody that reflected a baseline level of Ser897 phosphorylation as 
demonstrated by the knock down of the signal upon incubation with CIP. 
Importantly, the incubation with p90RSK1 strongly increased Ser897 
phosphorylation; again this signal was almost completely abolished upon CIP 
treatment (Figure 18). 
 
 
 
 
Figure 18. p90RSK phosphorylates EPHA2 on Ser897 in vitro. Recombinant 
GST-tagged EPHA2 cytosolic domain (amino acids 560-976) was incubated alone or 
with GST-tagged full-length p90RSK for 15 min at 30 °C in kinase buffer. The assay 
reaction was splitted in two tubes and, after SDS-PAGE, the resulting membranes 
were blocked in TBS-BSA 0.1% for 1h, and subjected or not to CIP treatment (68 
mU/µg, 1h, 37°C) before immunoblotting with pSer897 EPHA2, total EPHA2 or 
p90RSK antibodies. 
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 To confirm these findings and to finely map the phosphorylation target 
sequence, we generated minimal EPHA2 peptides either containing the wild 
type sequence spanning Ser897 (wt), the replacement of S897 with the non-
phosphorylatable Alanine residue (S897A), or all the 4 Serine/Threonine 
residues substituted by Alanine residues (4S/T→A). A peptide where the 
RXXpS consensus sequence was disrupted by replacing the Arginine at 
position -3 with a Lysine residue (R894K) was also used. Then, we tested in 
vitro the capability of recombinant p90RSK of inducing detectable 
phopshorylatio of these peptides. Incubation with p90RSK and γ-32P ATP 
induced a robust incorporation of 32P in the wt peptide but not in its mutated 
versions. These data indicated that p90RSK is able to phosphorylate a EPHA2 
peptide containing S897, that this phosphorylation depends on the integrity of 
S897 and finally that it depends on the presence of a consensus sequence 
(Arginine at position -3) for the phosphorylation mediated by the N-terminal 
p90RSK kinase domain (NTKD) (Figure 19). 
 Altogether, these findings proved that p90RSK is able to phosphorylate 
Ser897 both in intact cells as well as in vitro. 
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Figure 19. p90RSK phosphorylates EPHA2 peptides on Ser897 in vitro. 
Recombinant p90RSK1 (100 ng) was incubated with the indicated EPHA2 
synthetic peptides (wild-type, S897A mutant, R894K mutant, and 4S/TA 
mutant) in the presence of γ-32P ATP for 15 min at 30°C. Peptides were spotted 
onto P81 filters, and the incorporation of 32P was measured by Cherenkov counting 
and reported as counts per minute (CPM). Data shown are the mean ± SD of three 
independent experiments. 
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4.5 Ser897 phosphorylation of EPHA2 regulates growth 
of thyroid cancer cells  
 
 
 To explore the significance of EPHA2 phosphorylation on Ser897 in 
thyroid cancer cells, we performed a siRNA-based EPHA2 knock-down 
combined with EPHA2 rescue in human 8505C and in rat PC-BRAF cells. As 
shown in Figures 20 and 21, EPHA2 silencing reduced number of both cell 
types compared to control siRNA transfected cells. The co-transfection with a 
GFP-tagged EPHA2 construct was able to rescue number of cells in both cases; 
rescued levels of EPHA2 were confirmed by the immunoblot experiment 
reported in Figure 22. More importantly, a non-phosphorylatable S897A 
mutant version of EPHA2 was virtually inactive in this assay in both cell lines 
(Figure 20-21). In the case of 8505C cells both Trypan-blue exclusion assay 
and dosage of PARP cleavage indicated that effects of EPHA2 silencing were 
cytostatic neither than apoptotic (data not shown). 
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Figure 20. Effects of EPHA2 silencing on growth of 8505C thyroid cells. EPHA2 
expression was knocked-down by siRNA transfection in 8505C cells. Control siRNA 
(siCTRL) was used as negative control. Upon 36h of silencing, rescue of EPHA2 
expression was obtained upon transfection with wild-type (wt) or S897A mutant 
(S897A) EPHA2. 36h after rescue, cells were counted and reported as the average 
values of triplicate dishes ± SD. These data are representative of three independent 
experiments. 
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Figure 21. Effects of EPHA2 silencing on growth of BRAF V600E expressing PC 
thyroid cells. EPHA2 expression was knocked-down by siRNA transfection in PC-
BRAF V600E cells. Control siRNA (siCTRL) was used as negative control. Upon 36h 
of silencing, rescue of EPHA2 expression was obtained upon transfection with wild-
type (wt) or S897A mutant (S897A) EPHA2. 36h after rescue, cells were counted and 
reported as the average values of triplicate dishes ± SD. These data are representative 
of three independent experiments. 
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Figure 22. EPHA2 silencing in BRAF mutant thyroid cells. 8505C (A) or PC-
BRAF V600E (B) were treated as shown in Figures 20-21. Upon 36h of silencing, 
rescue of EPHA2 expression was obtained upon transfection with wild-type (wt) or 
S897A mutant (S897A) EPHA2. 36h after rescue, cells were lysated and 
immunoblotted with indicated antibodies. Tubulin or actin were used for 
normalizzation. These experiments were performed at least three times. 
 
 
 
 4.6 Ser897 phosphorylation of EPHA2 regulates motility 
 of thyroid cancer cells  
 
 
 As previously demonstrated by Miao and coworkers (2009 and 2015) 
and, more recently, by Zhou and coworkers (2015), Ser897 phosphorylation of 
EPHA2 regulates cancer cell migration and invasion. We therefore tested 
whether this applied also to thyroid cancer cells.  
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siRNA-mediated knock-down of EPHA2 reduced the ability of 8505C cells to 
close an artificial wound, while transfection with wt EPHA2, but not with the 
S897A mutant, was able to restore the ability of closing the scratch (Figure 
23).   
 
 
 
Figure 23. Effects of EPHA2 silencing on in vitro migration of 8505C cells. 
Wounds of about 300 µM width were inflicted to monolayers of 8505C cell cultures 
treated (EPHA2 knock-down followed by EPHA2 transfections) as in Figures 20 and 
22. Wound closure was measured after 24 (t1) and 48 (t2) h. The vertical dotted lines 
indicate the margins of wound. Representative micrographs are shown: magnification 
= 6X. These figures are representative of at least three independent assays. 
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 5.  DISCUSSION 
 
 
5.1 Role of EPHA2 phosphorylation on Serine 897 in 
thyroid neoplastic transformation 
 
 Here we have explored role of EPHA2 in thyroid carcinogenesis. Our 
interest in studying EPHA2 was prompted by a previous screening conducted 
in our laboratory to identify protein kinases involved in thyroid cancer cell 
viability (Cantisani et al. 2016). In this screening, we used a library of synthetic 
siRNAs targeting the 518 human protein kinases and we tested the capability of 
the individual siRNAs of blunting viability of the RET/PTC1-positive human 
papillary thyroid carcinoma TPC1 cell line (Table 3). Silencing of about 50 
genes reduced TPC1 cell viability. Then, the number of positive hits was 
reduced to 14 based on subsequent validation experiments involving the 
identification of the most potent siRNAs (able to reduce cell viability by at 
least 30%), through the use of control siRNAs, and the use of a control cell line 
(NTHY). Proliferation of additional thyroid cancer cell lines (BCPAP, 8505C 
and CAL62 cell lines) with different histotypes and different complements of 
genetic lesions with respect to TPC1 (BCPAP and 8505C cells are positive for 
BRAF V600E, CAL62 are positive for KRAS G12R) (Table 3) was also 
inhibited by virtually all 14 antiproliferative hits. The 14 hits included EPH 
receptors (EPHA2, EPHA7, EPHB2, EPHB6), SRC family kinases (FYN, 
HCK), kinases of the p38 and JNK signaling cascades (MAP3K7IP1, 
MAPKAPK2 and PKN1) or of the PI3K/mTOR (AKT2) or the PKA/cyclic 
AMP pathway (PRKACB) [Cantisani et al. 2016].  
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Among these hits, we foused in particular on EPHA2 based on previous 
evidence supporting the role of this receptor in different human cancer types, 
including thyroid carcinoma (see below). 
 Data discussed in this Dissertation show that EPHA2 is strongly 
expressed in a panel of human thyroid carcinoma cells lines deriving from both 
RET/PTC1- or BRAF V600E-positive papillary thyroid carcinomas or BRAF- 
or KRAS G12R-positive anaplastic thyroid carcinomas. In these cell lines, 
EPHA2 is robustly phosphorylated on Ser897. RNAi-based silencing 
experiments confirmed the role of EPHA2 in thyroid cancer cells proliferation 
and motility and rescue experiments with wild-type and S897A mutant EPHA2 
showed that Ser897 is essential for these oncogenic effects. Transfection of rat 
thyroid PC cells with BRAF V600E and RET/PTC variants confirmed the 
capability of the two oncogenes of inducing expression and Ser897 
phosphorylation of EPHA2. Use of a Doxycycline-inducible PC-RET/PTC3 
model showed, in a time-course experiment, that oncogene expression was 
directly linked to Ser897 phosphorylation. Phosphorylation on Ser897 was 
impaired by chemical inhibitors of the driving oncoprotein (RET/PTC1 in the 
TPC1 and BRAF V600E in the 8505C cell lines, respectively) and by 
inhibitors of the MAPK (MEK) pathway. Since Ser897 is embedded in a 
consensus sequence (Arginine at position -3 with respect to the 
phosphorylatable residue) for the phosphorylation mediated by AGC family 
Serine/Threonine kinases, we hypothesized that a member of this family that 
was involved in the MAPK cascade could be directly or indirectly involved in 
EPHA2 Ser897 phosphorylation and pointed to ribosomal S6 kinase p90 
(p90RSK) as a reasonable candidate.  
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Accordingly, both p90RSK1 and p90RSK2 were consistently expressed in 
thyroid carcinoma cells and a chemical inhibitor of p90RSKs (BI-D1870) was 
able to reduce phospho-Ser897 content of EPHA2. Similarly, p90RSK1 
overexpression in ϕχ cells increased Ser897 phosphorylation, confirming again 
that, directly or indirectly, p90RSK was able to phosphorylate EPHA2 on 
Ser897. Finally, an in vitro kinase assay using the cytosolic EPHA2 domain as 
a substrate showed that recombinant p90RSK1 was able to increase reactivity 
with a specific phospho-Ser897 antibody and another in vitro kinase assay 
using as substrate peptides spanning the EPHA2 sequence containing S897 
proved that p90RSK1 was able to directly phosphorylate Ser897; such a 
phosphorylation required the Arginine residue at position -3 with respect to 
Ser897, consistent with the substrate selectivity of p90RSK. However, while in 
BRAF-mutant thyroid cancer cells p90RSK is the dominant Ser897 EPHA2 
kinase, a role of AKT in RET/PTC-positive cells can also be envisaged. 
 Our findings are consistent with previously published observations. In 
particular, Miao and coworkers showed that while EFNA1-mediated RTK 
activation of EPHA2 blunted migration of glioma and prostate cancer cells. 
Ser897 phosphorylation mediated by AKT promoted in an EFNA1-
independent and RTK-independent manner cell migration, multiple growth 
factors (EGF, FGF, PDGF, HGF) stimulated Ser897 phosphorylation and this 
event in human glioma samples correlated with tumor grade (Miao et al. 2009). 
Mechanistically, Ser897-mediated and EFN- and RTK-independent EPHA2 
activity promoted invasiveness and stem cell properties of multiple glioma cell 
lines (Miao et al. 2015). Of note AKT is part of the AGC family kinases as 
well as p90RSK and the two kinases share a common consensus sequence for 
phosphorylation (see below) [Mendoza et al. 2011]. More recently, Zhou and 
coworkers reported that TNF-α induced Ser897 phosphorylation of EPHA2, 
while EFNA1 induced its phosophorylation on Y588 in HeLa cells.  
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Moreover, similar to our findings p90RSK was able to directly phosphorylate 
Ser897 and this mediated motility of breast cancer cells as demonstrated by the 
use of p90RSK siRNAs as well as chemical inhibitor BI-D1870. Finally, the 
p90RSK-EPHA2 Ser897 pathway was found constitutively active also in 
BRAF or NRAS mutant melanoma cell lines (Zhou et al. 2015). 
 
 
5.2 Role of EPHA2 in cancer 
 
 EPHA2 is a member of the A family of EPH receptors and it is the 
EPHA subtype most commonly involved in human cancer.  
 Physiological role of EPHA2 seems to be mainly related to regulation 
of cell-to-cell interactions, based on its capability of regulating components of 
tight and adherens junctions (Miao et al. 2009). In mice, the only two 
phenotypes related to EPHA2 ablation are the presence of a kinked tail and 
cataract. Interestingly, EPHA2 (at chromosome 1p36) rare genetic variants 
have been found to exert a strong linkage with cataract occurrence in 
Caucasians. One of these variants, Arg721Gln increases basal kinase activity of 
EPHA2 (Jun et al. 2009).  
 While its role in development is still poorly understood, EPHA2 has a 
strong association with cancer. EPHA2 is rarely mutated but it is frequently 
overexpressed in carcinomas of the breast, lung, and several other cancer types 
(Amato et al. 2014; Brantley-Sieders et al. 2008; Hafaner et al. 2006; Hatano et 
al. 2005; Herath et al. 2006; Kinch et al. 2003; Miyazaki et al. 2003; Nakamura 
et al. 2005; Walker-Daniels et al. 1999; Xu et al. 2014; Zelinski et al. 2001).  
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 In particular, EPHA2 has been involved in thyroid carcinoma (Lisabeth 
et al. 2013). In an immunohistochemistry-based screening, EPHA2 was 
demonstrated to be upregulated in papillary carcinomas (Karidis et al. 2011) 
and it was essential for invasion of the FTC-238 and FTC-133 thyroid cancer 
cell lines (O'Malley et al. 2012).  
 In non-small cell lung carcinomas (NSCLC), EPHA2 was associated to 
poor outcome and its genetic disruption in model of KRAS-induced NSCLC 
impaired tumor growth. In vitro EPHA2 knock-down reduced growth and 
survival of NSCLC cell lines and the EPHA2 ATP-competitive kinase inhibitor 
ALW-II-41-27 reduced tumorigenicity in a NSCLC xenograft model (Amato et 
al. 2014). More recently, EPHA2 inhibition by ALW-II-41-27 was also 
demonstrated to be able to overcome resistance of NSCLC cell lines to the 
EGFR TKIs erlotininb or AZD9291 (Amato et al. 2016).  
 In mammary carcinomas, EPHA2 has been reported to be ovrexpressed 
in aggressive subtypes featuring a poor prognosis. Moreover, EPHA2 ablation 
reduced initiation and metastatic progression of mammary carcinomas in 
MMTV-ERBB2 transgenic mice. Accordingly, EPHA2 formed a protein 
complex ERBB2 and enhanced activation of RAS/MAPK and Rho pathways 
(Brantley-Sieders et al. 2008). 
 In melanomas, EPHA2 was recently reported to be involved in 
resistance and adaptation to BRAF/MEK kinase inhibitors. Chronic exposure 
to BRAF inhibitors caused upregulation of EPHA2 and of its phosphorylation 
on Ser897 accompanied by increased cell invasion and reduced expression of 
EFNA1 ligand (Paraiso et al. 2010).  
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Similarly, in melanoma cell lines that developed resistance to BRAF chemical 
inhibition as well as in tumor specimens from patients who relapsed upon 
BRAF inhibitor treatment, EPHA2 was found overexpressed and hyper-
phosphorylated on Ser897 and treatment with ALW-II-41-27 EPHA2 TKI was 
able to suppress BRAF inhibitor-resistant melanoma cells (Miao et al. 2014) 
 Finally, knock-out mice showed that EPHA2 was dispensable for 
normal hematopoiesis as well as for acute myleoid leukemias initiated by the 
MLL-AF9 oncogene, however radiolabeled anti-EPHA2 monoclonal 
antibodies blocked leukemogenesis in experimental mice (Charmsaz et al. 
2015) 
 Accordingly, EPHA2 has been considered as a promising molecular 
target for cancer treatment and various tools are being explored to hit EPHA2 
in different cancer types, including EPHA2 monoclonal antibody, polyspecific 
antibodies designed to target different EPH simultaneously, soluble or 
endotoxin-conjugated EFNA1, small molecule tyrosine kinase inhibitors (such 
as ALW-II-41-27), gold- or polyethylene glycol (PEG)-coated EFNA1 
nanoschells, human adenoviruses engineering with EFA1 extracellular domain 
or with EFNA1 mimetic homing peptide (YSAYPDSVPMMSK named YSA), 
functionalized YSA-nanocarriers for drug delivery (www.clinicaltrials.gov; 
Guo et al. 2015; Tandon et al. 2011; Ozcan et al. 2015). Moreover, some 
studies have tested the combination of EPHA2-targeting therapies with 
chemotherapeutics or other targeted therapies, such as combination of EPHA2-
antibody and paclitaxel in ovarian tumors, EPHA2 siRNA with FAK or Src 
siRNAs, EPHA2 antibody with tamoxifen, EPHA2 inhibitors and gemcitabine 
in pancreatic cancer (Koch et al. 2015; Amato et al. 2016; Quinn et al. 2016). 
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5.3 Role of MAPK signaling cascade in thyroid cancer 
 
 Thyroid cancer genome is dominated by lesions targeting the MAPK 
signaling cascade (Nikiforov et al. 2011; Xing, 2013; Xing et al. 2013; Wells 
and Santoro 2014) (Figure 24). This pathway is initiated by the activation of a 
transmembrane receptor, typically a growth factor tyrosine kinase receptor 
(RTK), at the plasmamembrane level. This is followed by SOS exchange factor 
recruitment to the inner side of the membrane and by GTP-for GDP exchange 
on membrane-bound RAS family p21 small GTPases. GTP-p21RAS in turn 
mediates dimerization and activation of RAF family Serine/Threonine kinases 
(ARAF, BRAF, CRAF) that in turn phosphorylate and activate MEK1/2 at 
positions 217 and 221 in the activation loop. Activated MEKs dually 
phosphorylate p44 and p42 ERKs (MAPK) at Threonine 202 and Tyrosine 204, 
which results in ERK activation. Once active, ERKs can either directly or 
indirectly through additional kinases mediate the phosphorylation and 
activation of transcription factors, including ELK1, MYC, STAT1, thereby 
promoting multiple cell responses (Mendoza et al. 2011; Pearce et al. 2010). 
 p90RSK family kinases (p90RSK1-4) are prototypic effectors of the 
MAPK signaling cascade. p90RSK is composed of a regulatory C-terminal 
kinase domain (CTKD) that belongs to the calmodulin dependent kinase family 
and an effector N-terminal kinase domain (NTKD) that belongs to the AGC 
kinase family separated by a linker region. ERKs mediate phosphorylation of 
the p90RSK C-terminal kinase domain (CTKD) on Thr573, and of linker 
region on Thr359 and Ser363. This initiates a sequence of events leading to 
phosphorylation of the linker on Ser380 by the CTKD and of the NTKD on 
Ser221 by PDK1 finally resulting in the activation of the NTKD (Moritz et al. 
2010; Romeo et al. 2012; Galan et al. 2014). 
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 MAPK is a prototypical oncogenic signaling pathway; several evidence 
points to a role of p90RSKs, in particular, in cancer. p90RSK is overexpressed 
in lung cancer where it has been considered a suitable therapeutic target 
(Poomakkoth et al. 2016). p90RSK1 is involved in prostate cancer cell growth 
and metastatization (Yu et al. 2015). p90RSK inhibition was found to impair 
selectively anchorage-independent growth of several tumor cell types 
(Aronchik et al. 2014). p90RSK was involved in squamous cell carcinomas by 
increasing MYC expression and cell invasion (Degen et al. 2013). Finally, 
p90RSK was involved in BRAF-mediated melanoma cell growth (Romeo et al. 
2013) and in breast cancer stem cell maintenance and trastuzumab resistance 
via the phosphorylation of YB1 (Stratford et al. 2012; Astanehe et al. 2012) 
 The various subtypes of thyroid cancer are typically associated to 
oncogenic conversion of MAPK, with MTC frequently harboring RET or RAS 
mutations, PTC associated to RAS (FV-PTC) or BRAF V600E (or other less 
common BRAF lesions) and RET or other RTKs lesions (CV-PTC), FTC 
harboring in about half of the cases RAS mutations, and finally ATC 
commonly harboring either RAS or BRAF lesions (Nikiforov et al. 2011; Xing 
et al. 2013; Wells and Santoro 2014). Importantly, p90RSK has been found 
consistently phosphorylated in human papillary thyroid cancer samples, in 
particular in RAS-mutant PTCs (Cancer Genome Atlas, 2014). 
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Figure 24. MAPK pathway activation mediates EPHA2 Ser897 phosphorylation 
through p90RSK in thyroid cancer cells. 
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6. CONCLUSIONS 
 
 
 Mechanisms through which p90RSKs can contribute to neoplastic 
transformation are diverse. In some cases, oncogenic activity of p90RSK has 
been demonstrated to be mediated by activation of specific transcription 
factors, such as YB1 (Shiota et al. 2014). In other cases, p90RSK has been 
involved in overcoming DNA damage checkpoint arrest through 
phosphorylation of MRE11 and CHEK1 (Chen et al. 2013; Ray-David et al. 
2013). p90RSKs are able to blunt apoptosis via phosphorylation of APAF1 
(Kim et al. 2012). Finally, p90RSKs are able to promote cell growth via 
phosphorylation of CDC25 isoforms (Wu et al. 2014). Moreover, the notion 
that p90RSK is able through phosphorylation of modulating the activity of 
membrane proteins is not unprecedented. For instance, p90RSK is able to 
phosphorylate β4-integrin on T1736 thus reducing adhesion through 
hemidesmosomes (Te Molder et al. 2015)  
 In this context, the mechanism through which p90RSK-mediated 
Ser897 phosphorylation of EPHA2 functions in thyroid cancer is still unclear. 
Two possible mechanisms can be conceived.  
 One possibility is that phospho-Ser897 acts by recruiting intracellular 
signaling transducers to EPHA2. Accordingly, Ephexin 4 interaction with 
EPHA2 is regulated by Ser897 phosphorylation. Ephexin 4 is a member of 
Dbl-type guanine nucleotide exchange factors (GEFs) family. It is able to 
promote cell proliferation and survival by activating RhoG and Rac small 
GTPases through the ELMO–Dock180 or ELMO–Dock4 complexes as well as 
the PI3K/Akt signaling pathway (Hiramoto-Yamaki et al. 2010; Kawai et al. 
2013).  
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We are currently exploring whether Ephexin 4 is expressed in thyroid cancer 
cells and plays any role in EPHA2 signaling. 
 Another possibility is that Ser897 phosphorylation modulates in some 
way EPHA2 signal trasduction. In this frame, while ligand-mediated EPHA2 
oligomerization leads to increased tyrosine phosphorylation, cell contraction 
and reduced tumor growth and motility, EPHA2 mutants that are unable to 
dimerize feature increased motility promoting effects, Ser897 phosphorylation, 
and reduced tyrosine-phosphorylation, thus pointing again to opposite effects 
mediated by ligand mediated oligomerization/EPHA2 tyrosine phosphorylation 
and AGC kinases-mediated Ser897 phosphorylation (Singh et al. 2015). We are 
currently exploring whether tyrosine kinase activity of EPHA2 influences or is 
influenced by Ser897 phosphorylation and whether this has any impact on the 
ability of EPHA2 of driving intracellular pathways such as the MAPK and the 
AKT one. 
 Elucidating this pathway will be crucial to devise strategies to intecept 
it to blunt thyroid tumorigenesis. 
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Publications summary 
 
 
MC Cantisani, A Parascandalo, M Perälä, C Allocca, V Fey, N Sahlberg, F 
Merolla, F Basolo, MO Laukkanen, OP Kallioniemi, M Santoro, MD 
Castellone – A Loss-of-Function Genetic Screening Identifies Novel 
Mediators of Thyroid Cancer Cell Viability, Oncotarget, in press 
In this study we have performed a loss of function screening by transfecting 
thyroid cancer cells (TPC1 cells) with a library of siRNA targeting the whole 
human kinome in order to discover kinases involved in thyroid cancer cell 
viability. Our data identify a novel set of thyroid cancer regulators, including 
several members of EPH receptor tyrosine kinase family as well as SRC and 
MAPK (mitogen activated protein kinases) families. 
 
 
G Vecchio, A Parascandolo, C Allocca, A Strazzulli, M Moracci, C 
Ugolini, F Basolo, MD Castellone, M Santoro, N Tsuchida – 
Downregulation of FUCA-1 in human thyroid anaplastic carcinomas - 
manuscript in preparation 
In this work we have studied the role of the alpha-L-Fucosidase-1 (FUCA-1) in 
thyroid cancer. This enzyme is involved in the removal of fucose from glycans 
and has been shown to be downregulated in highly aggressive and metastatic 
histotypes of human cancers. Our data demonstrate that the expression is 
significantly reduced in anaplastic thyroid cancer (ATC) as well as thyroid 
cancer cell lines. Moreover, the transfection of FUCA-1 in ATC cells is able to 
impair their tumorigenic properties. 
